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This work was designed as a proof-of-principle concept or prototype to show the effect of 
protein-assisted targeting of DNA to specific genomic loci. Two strategies were 
employed to deliver the DNA with the aim that once inside the cell the DNA would be 
delivered to the target sequence by the assistance of a protein. In our case, the chosen 
protein was the site-specific meganuclease I-SceI. The first strategy described herein was 
to bind the targeting DNA to I-SceI by the use of a fusion protein between I-SceI and a 
known DNA-binding domain, the GAL4-DBD. The second strategy involved using a 
DNA aptamer to I-SceI to link the targeting DNA and I-SceI. Testing in vivo revealed that 
in our human cells (HEK-293) single-stranded DNA was more efficient at gene targeting 
than double-stranded DNA. In order for the first strategy to work, we needed to have 
some region of double-stranded DNA. We found that in human cells, it was better for 
gene targeting to have that double-stranded DNA on the 5’ side of our targeting DNA. 
We also used gel shift assays to confirm binding by our candidate DNA-binding domain, 
the GAL4-DBD. We were unable to detect expression of the fusion protein of I-SceI and 
the GAL4-DBD. 
 
For the second strategy we were able to construct an aptamer to I-SceI using a variant of 
the systematic evolution of ligands by exponential enrichment (SELEX). The I-SceI 
aptamer was synthesized as part of a longer DNA molecule containing homology to a 
target locus. Using this chimeric oligonucleotide (part aptamer, part DNA repair region) 
testing was done in both yeast and human cells. Aside from instances where the 
 
aptamer’s secondary structure may have been compromised, the aptamer containing 
oligonucleotide stimulated repair at a rate 2 to 15-fold higher than the non-selected 
control sequence. These experimental results show that by delivering targeting DNA 
within close proximity to the site of modification, gene targeting frequencies can be 








1.1 DOUBLE-STRAND BREAK (DSB) REPAIR AND GENE TARGETING 
A DNA double-strand break (DSB) is generally regarded as the most severe DNA 
damage. DSBs can be caused by a variety of exogenous sources including ionizing 
radiation (IR), radiomimetic chemicals, and ultraviolet light, as well endogenous sources 
like collapsed replication forks or programmed endonucleolytic cleavage by programmed 
cellular endonucleases during meiosis or V(D)J recombination (Chapman, Taylor et al. 
2012). A DSB if left unrepaired can be a lethal cellular event. There are two main repair 
pathways used by the cell to correct DSBs, specifically homologous recombination (HR) 
and non-homologous end-joining (NHEJ). HR involves resection of the two 5’ DNA ends 
generated by the DSB, a search for homologous DNA by the 3’ overhanging DNA tails, 
annealing to homologous DNA, and repair of the DSB (Aylon and Kupiec 2004). Also 
there is a variant of HR known as single-strand annealing (SSA). SSA is a special case of 
DSB repair in which a DSB occurs between two repeated DNA sequences oriented in the 
same direction (Ivanov, Sugawara et al. 1996). The two 5’ DNA ends generated after the 
DSB are resected in a 5’ to 3’ manner and the remaining two single-stranded 3’ tails find 
homology with each other at the repeated sequence. The ssDNA sequences anneal, the 
unannealed tails are removed, and the resulting repair causes a deletion since the two 




include break-induced replication (BIR), synthesis-dependent strand annealing (SDSA), 
or homologous recombination involving the formation of two Holliday junctions known 
as double Holliday junction (dHJ) (Heyer, Ehmsen et al. 2010). Each of these repair 
pathways is different but they are all similar in the fact that after the DSB is generated in 
order for these repair pathways to function, the DNA ends must be resected in a 5’ to 3’ 
manner. Likewise, in each of these pathways the 3’ ssDNA tails then invade a 
homologous template, displacing its DNA and forming a D loop (the name for the 
structure after displacement), and then the homologous template is used to synthesize 
through the gap that was generated by the DSB. 
 
The other main pathway for repairing DSBs involves NHEJ, which repairs the DSB by 
religating the free DNA ends generated from the break. The difference between NHEJ 
and HR is that NHEJ relies on very little (in the case of microhomology-mediated end 
joining) or no homology while HR requires a homologous template. Although simple 
religation can lead to accurate repair by NHEJ, the majority of DSBs in cells arise from 
DNA damage in the form of ionizing radiation, reactive oxygen species (ROS), and 
chemical agents that typically do not leave behind easily ligatable products, but rather 
“dirty ends,” which must undergo processing before NHEJ can occur (Woodbine, 
Brunton et al. 2011). In this capacity, NHEJ often leads to misalignment of the DNA 
ends, deletion of genetic information, or the insertion of DNA fragments at the break site. 
 
Gene targeting is the in situ modification of a specific genomic locus by HR through the 




homology to the targeted DNA sequence at or near the DSB, the DSB can be repaired. 
Additionally, by modifying the exogenous DNA to have non-native sequence information 
flanked by regions of homology to the DSB, HR repair can actually introduce new DNA 
sequences or conversely remove pre-existing DNA sequences. Thus, gene targeting can 
be used to insert or delete sequences of DNA at a specific genomic locus. 
 
The alternative to gene targeting is known as random integration or illegitimate 
recombination, whereby the exogenously introduced DNA integrates at a random 
genomic locus. Random integration occurs due to NHEJ between the exogenously 
introduced DNA and a DSB somewhere in the endogenous genomic DNA (Iiizumi, 
Kurosawa et al. 2008). The exogenous DNA is ligated in between the ends of the DSB, 
leading to integration of the exogenous DNA while at the same time disrupting the native 
DNA sequence. 
 
1.2 THE ADVANTAGES OF GENE TARGETING OVER RANDOM 
INTEGRATION 
As stated, gene targeting and random integration are two outcomes when exogenous 
DNA is introduced into the cell. Several examples of “gene augmentation” exist which 
employ random integration to introduce an exogenous gene into the human genome for a 
therapeutic outcome. Severe combined immunodeficiency (SCID) was the first disease to 
be treated with gene therapy, specifically gene augmentation, in the early 90s (Blaese, 
Culver et al. 1995, Bordignon, Notarangelo et al. 1995, Kohn, Weinberg et al. 1995). In 




given a good copy of the ADA gene. Since then, gene augmentation has been used to 
treat not only ADA- SCID (Aiuti, Slavin et al. 2002), but X-linked SCID (Cavazzana-
Calvo, Hacein-Bey et al. 2000), epidermolysis bullosa (EB) (Mavilio, Pellegrini et al. 
2006), β thalassaemia (Sadelain 2006), and many other genetic disorders (Ginn, 
Alexander et al. 2013). 
 
Although not as widely used as gene augmentation strategies, gene targeting has several 
advantages over random integration. As can be derived from its name, random integration 
can lead to unforeseen consequences including cis or trans-activation of a gene close to 
where the transgene was inserted, disruption of regulatory elements, or the creation of 
aberrant fusion proteins all of which could lead to diseases such as cancer. These kinds of 
insertional mutagenesis, although rare, present a real risk for gene therapy patients. In 
2002 two patients, followed by one patient in 2006 and one patient in 2007, in X-linked 
SCID trials in France and London were shown to have developed a leukemia-like 
disorder after the insertional mutagenesis of the therapeutic vector which activated an 
oncogene (Hacein-Bey-Abina, Von Kalle et al. 2003). Aside from the risk associated 
with gene augmentation, from a therapeutic aspect there are many genetic disorders 
caused by dominant negative mutations (Huntington’s, myotonic dystrophy, and brittle 
bone disease to name a few) where the mutated gene product has an antagonistic effect 
on the wild-type protein. In these disorders, even successful integration of a transgene 
will do nothing to alter the disease. Likewise, random integration of a transgene cannot 




function of a particular gene. Gene targeting is logically the best choice for gene therapy 
and functional studies because it proceeds in a controlled manner, modifying only the 
DNA of interest, and not causing unnatural expression in surrounding genes. 
 
1.3 STIMULATING GENE TARGETING IN MAMMALIAN CELLS 
As stated, gene targeting has many advantages over random integration and in human 
cells would be a powerful tool for researchers interested in functional analysis of genes as 
well as patients suffering from genetic disorders. The primary limitation of gene targeting 
is the low frequency with which it spontaneously occurs in mammalian cells, happening 




 treated cells (Vasquez, Marburger et al. 2001). The 
low frequency of gene targeting, which relies on homologous recombination (HR), is due 
in part to the much higher frequency of non-homologous end joining (NHEJ), which 




 treated cells (Vasquez, Marburger et al. 
2001). 
 
Currently, there are several strategies for increasing gene targeting in mammalian cells. 
Stimulation of gene targeting by generating a DSB at the target site increased the 
frequency of gene targeting several orders of magnitude in bacteria (Nussbaum, Shalit et 
al. 1992), yeast (Storici, Durham et al. 2003), plants (Puchta, Dujon et al. 1993), fruit 
flies (Banga and Boyd 1992), mice (Rouet, Smih et al. 1994), human embryonic stem 
cells (Smih, Rouet et al. 1995), and many other cell types. Another strategy to increase 
gene targeting in mammalian cells has been achieved through the over-expression of key 




led to a 10-fold increase in gene targeting in mouse cells (Shcherbakova, Lanzov et al. 
2000), likewise over-expression of yeast Rad52 led to a 37-fold increase in gene targeting 
in human cells (Di Primio, Galli et al. 2005). Conversely, another strategy for increasing 
gene targeting in human cells involves decreasing the amount of the DSB repair through 
the pathway of NHEJ. In mouse embryonic stem cells an increase in gene targeting was 
seen in Ku70 (6-fold), XRCC4 (2-fold), and DNAPK-cs (2-fold) deficient cell lines 
(Pierce, Hu et al. 2001) and a 3-fold increase in Chinese hamster ovary cells lacking 
DNAPK-cs (Allen, Kurimasa et al. 2002). Similarly, knockdown of KU70 and XRCC4 in 
human colon cancer cells lead to a 30-fold increase in gene targeting (Bertolini, Bertolini 
et al. 2009). 
 
Another strategy for increasing gene targeting not focused on increasing HR or 
decreasing NHEJ was developed whereby knocking down human SMC1, important for a 
certain type of HR, gene targeting increased (Potts, Porteus et al. 2006). The sister 
chromatid is the normal donor DNA for HR repair, but in the case of gene targeting an 
exogenous DNA acts as the donor for repair. HR with the sister chromatid actually 
hinders gene targeting by exogenously introduced DNA. By knocking down hSMC1 
which is required for sister chromatid HR, gene targeting increased four-fold. The 
proteins hSMC1 and hSMC3 form the cohesin complex which is responsible for keeping 
sister chromatids in close proximity to each other during a DSB. Without close proximity 




shifting repair of the DSB more toward HR with the exogenous sequence (gene 
targeting). 
 
1.4 SITE-SPECIFIC ENDONUCLEASES 
As previously discussed, a targeted DSB stimulates gene targeting several orders of 
magnitude. There are two main methods to generate a targeted DSB. The first 
characterized method for generating a site-specific DSB was to make use of naturally 
occurring “homing” endonucleases or meganucleases. Homing endonucleases are 
restriction enzymes which generate DNA double-strand breaks (DSBs) at defined genetic 
loci, and they have high specificity due to a long recognition sequence (12-40bp) (Belfort 
and Roberts 1997). Although homing endonucleases could stimulate gene targeting 
1,000-fold or more there was an inherent limitation to their use for gene therapy or 
functional analysis. In order to increase gene targeting at a specific locus, that locus 
would need to contain the long recognition sequence of the homing endonuclease close to 
the desired area of modification. Obviously, a more modular approach was needed and 
zinc finger nucleases (ZFNs) fulfilled that role. ZFNs are chimeric proteins composed of 
a DNA-binding domain, a series of zinc finger motifs, fused to the non-specific nuclease 
domain of the FokI endonuclease. When two ZFNs dimerize, the FokI domains are able 
to create a DSB at the targeted site (Kim, Cha et al. 1996). ZFNs seemed to be a modular 
solution to the problem of site-specific DSBs, although binding by ZFNs was 
complicated. ZFN binding was theoretically modular because each “finger” domain 
recognized a specific three nucleotide base pairs. The problem was that this binding was 




sequence AAT alone, when fused with another finger it might recognize AAG. Due to the 
inability to predict ZFN context specific binding properties, empirical studies needed to 
be done for each locus to find the best ZFN pair. ZFNs could be engineered and selected 
for almost any sequence, but not in a straightforward or cost-effective manner. 
 
Fortunately, an alternative to zinc fingers known as transcription activator-like effectors 
(TALEs) have been developed. Working in much the same way as a ZFN, a TALEN is 
composed of a single TALE protein fused to a FokI nuclease domain. The key difference 
between TALEs and ZFs is that instead of combining several ZFs that are context 
specific a single TALE can be constructed with an easily designed sequence specificity. 
The TALE consists of a repeat variable domain (RVD) which contains several (2 to 40) 




 amino acids being 




 amino acids are responsible for 
recognizing a single base pair (Moscou and Bogdanove 2009). Following this TALE 
“code” one can efficiently design a site-specific TALE in silico, construct the TALEN, 
and then use it in vivo without the need for laborious empirical testing (Moscou and 
Bogdanove 2009). 
 
Although ZFNs may be replaced by TALENs for the reasons stated, recently there have 
been reports of a new class of modular site-specific endonucleases called clustered 
regularly interspaced short palindromic repeats (CRISPRs) and their CRISPR associated 
(Cas) proteins (Cong, Ran et al. 2013). These CRISPR/Cas systems differ from ZFNs and 




on guide RNA (gRNA) (Cong, Ran et al. 2013). Specific RNA generated from the 
CRISPRs acts to guide a nuclease which creates a DNA DSB at the target bound by the 
gRNA (Mali, Yang et al. 2013). 
 
1.5 THE HOMING ENDONUCLEASE I-SCEI 
As stated previously, homing endonucleases are restriction enzymes which generate 
DNA double-strand breaks (DSBs) at defined genetic loci, and they have high specificity 
due to a long recognition sequence (12-40bp) (Belfort and Roberts 1997). The term 
homing comes from self-splicing group I or group II introns or inteins that “home” in on 
a specific sequence on the host gene, and splice themselves into the unoccupied allelic 
site by generating a break at the site which then homologously recombines with the 
intron-containing allele. Homing endonucleases have been studied since the late 1970s, 
and one of the first homing endonucleases studied was called “Omega” which later 
became known as I-SceI, Intron (where it was found) – Saccharomyces cerevisiae (the 
genus and species) I (the first discovered) (Stoddard 2011). The I-SceI endonuclease’s 
natural function is to recognize a nonsymmetrical 18bp sequence of  5’ TAG GGA TAA 
CAG GGT AAT 3’ (Colleaux, D'Auriol et al. 1988) on the intron-less allele and generate 
a DNA double-strand break (DSB) at that location, propagating the intron containing 
allele and overwriting the previously intron-less allele through homologous 
recombination and gene conversion. I-SceI binds to its recognition sequence very 
specifically as a monomer, but without the presence of Mn or Mg it will only bind, and 
not cleave the target (Beylot and Spassky 2001). I-SceI is naturally found in the yeast 




present. I-SceI enters the nucleus, but has no known NLS and is thought to enter the 
nucleus by passive diffusion (Plessis, Perrin et al. 1992) (Thermes, Grabher et al. 2002). 
Although it does not have a known NLS, I-SceI is small (27 kDa) and basic in nature (pI 
= 10.08), and therefore should be able to freely diffuse through the nuclear pore (size 
limit of ~50kDa) (Lungwitz, Breunig et al. 2005). For this work I-SceI was chosen as our 
protein of interest due to its ability to stimulate gene targeting and its ability to target a 
specific DNA sequence. 
 
1.6 THE GAL4 DNA-BINDING DOMAIN (DBD)  
The 881 amino acid GAL4 protein from Saccharomyces cerevisiae is one of the most 
well-characterized and studied transcription factors, serving as an activator of the 
galactose metabolizing enzyme genes GAL1, GAL7, and GAL10 (Oshima 1982) 
(Laughon and Gesteland 1982). The GAL4 protein consists of an N-terminal DNA 
binding domain and dimerization domain (amino acids 1-74 or 1-147, with 1-147 
showing better DNA binding) that binds DNA through two cadmium ions in a Cd2Cys6 
helix-turn bimetal thiolate cluster (Baleja, Thanabal et al. 1997) as well as two 
transcription activating domains (amino acids 148-196 and 768-881) (Ma and Ptashne 
1987). Since 1989, the DNA binding domain (DBD) and the activating domain (AD) 
have been used separately to study protein-protein interactions by creation of two fusion 
proteins, one of GAL4’s DBD (1-147) with a protein of interest, and another fusion 
protein made up of GAL4’s AD (768-881) the idea being that if two proteins of interest 
interacted, they could thus activate transcription (Fields and Song 1989). This technique 




the components are commercially available. 
 
In addition to its use in the yeast 2 hybrid assay, the GAL4-DBD has started to be used in 
non-viral gene delivery strategies. The GAL4-DBD binds to a 17bp consensus sequence 
of 5’ CGGAGGACAGTCCTCCG 3’ (with a general binding pattern of 5’ 
cggrnnrcynyncnccg 3’) (Baleja, Thanabal et al. 1997). The delivery strategies usually 
involve using the GAL4-DBD as a fusion protein (not surprising given the availability of 
fusion protein vectors) where the GAL4-DBD acts as the DNA binding portion and the 
other parts of the chimeric protein are involved in DNA transport into the cell and/or 
other functions such as endosome escape. As examples, the GAL4-DBD has been fused 
to a single chain antibody for delivery (Wels, Groner et al. 1996), invasin (Paul, Weisser 
et al. 1997), anthrax toxin (Gaur, Gupta et al. 2002), and more recently to short cell 
penetrating peptides (CPPs) like the Tat peptide from HIV (Xu, Chi et al. 2010). It was 
shown that by using the GAL4-DBD and a plasmid containing two recognition sequences 
there was an enhancement of even calcium phosphate transfection, however in the same 
paper they showed that the nuclear localization sequence (NLS) of the GAL4-DBD is 
mutually exclusive of its DNA binding (Chan, Hubner et al. 1998). The authors reasoned 
that the GAL4-DBD enhanced the transfection by either DNA compaction or by 
protecting DNA from degradation once inside the cell, but not by its NLS. Additionally, 
in the same year, there was developed a fusion protein between the GAL4-DBD and the 
endonuclease FokI, generating a site-specific endonuclease in the process (Kim, Smith et 




highly specific (low nM Kd), and well-characterized (Taylor, Workman et al. 1991). In 
order to achieve our strategy of protein-assisted targeting we explored using a GAL4-
DBD I-SceI fusion protein. 
 
1.7 APTAMERS AND APTAMER SELECTION BY SYSTEMATIC EVOLUTION 
OF LIGANDS BY EXPONENTIAL ENRICHMENT (SELEX) 
Nucleic acid aptamers are short single-stranded DNA or RNA oligonucleotides that are 
capable of binding a ligand (protein, small molecule, or even living cells) with high 
affinity. They are also known as artificial antibodies because in addition to binding with 
high affinity, they also bind with high specificity. As an example, aptamers were selected 
for the small molecule theophylline and tested to see if they reacted with caffeine 
(another small molecule that differs from theophylline by only a single methyl group) and 
not only did the aptamer have strong binding with a 100nM Kd, but the aptamer bound 
theophylline 10,000 times stronger than it did caffeine
 
(Figure 1.1) (Jenison, Gill et al. 
1994). Aptamers have several advantages over antibodies, including ease and low cost of 
production which does not involve animals. Aptamers are less immunogenic than 
antibodies and are already being used as a therapeutic for human (Singerman, Masonson 
et al. 2008). A recent market report predicts that the aptamer market may be worth $1.8 
billion by 2014 (Jackson 2010). Aptamers are “evolved” from random sequences of 
DNA/RNA by a process known as systematic evolution of ligands by exponential 
enrichment (SELEX). The SELEX procedure involves the use of the random library of 
DNA/RNA sequences being incubated with the target, followed by a partitioning step to 




sequences, and then followed by an amplification step to generate a library of sequences 
enriched for binding (Figure 1.2). Using capillary electrophoresis (CE) allows for 
SELEX to be performed in a much shorter amount of time due to much more efficient 
partitioning and the obfuscation of aptamers binding to the ligand support (the ligand 
flows freely in buffer). In as little as one round of selection (Berezovski, Drabovich et al. 
2005), and almost always less than five, strong binding highly specific aptamers may be 
selected, as opposed to traditional SELEX which typically takes 10 or more rounds of 
selection. CE-SELEX generated aptamers have nM and sometimes pM level 
disassociation constants (Mosing, Mendonsa et al. 2005). CE-SELEX is a new 
technology first developed for use in 2004 and has yet to become commonly used 
(Mendonsa and Bowser 2004). In addition to strong binding aptamers in few rounds of 
selection, CE-SELEX typically generates a greater variety of unique aptamers compared 
to traditional SELEX. Aptamers are a versatile and interesting newly developing 






                 
 
Figure 1.1 Comparison of theophylline and caffeine structures. Shown above are the 
chemical structures for caffeine and theophylline, which differ only in a single methyl 
group. An aptamer was selected to bind to theophylline which showed an approximately 
320 nm Kd for theophylline but had a 3.5 mM Kd for caffeine (approximately 10,000 fold 




Figure 1.2 The Selective Evolution of Ligands by EXponential enrichment (SELEX) 
procedure. The ligand of interest is incubated with a random library of DNA. Sequences 
that form a suitable secondary structure bind to the ligand. These sequences are 
partitioned from the weaker binders and are eluted. After amplification of these binders, 




1.8 RESEARCH GOALS 
In order to assess the efficacy of our protein-assisted targeting system, three separate 
aims were devised. 
 
1.8.1 Construction and testing of a fusion protein between the I-SceI endonuclease and 
the GAL4-DNA binding domain (DBD) 
The essential part of protein-assisted targeting is the linking of the targeting DNA used to 
modify the endogenous DNA with our protein of interest, I-SceI. The first strategy for 
linking our targeting DNA to I-SceI involved a fusion protein between I-SceI and the 
GAL4-DBD. The GAL4-DBD is a specific DNA binding domain that recognizes a 17 bp 
sequence. Construction of fusion proteins along with in vivo testing of these constructs 
and different oligonucleotides designed to bind to the GAL4-DBD was done.  
 
1.8.2 Selection of a DNA aptamer using CE-SELEX 
One of the two strategies for protein-assisted targeting involved using a DNA aptamer to 
I-SceI. A modification on SELEX using capillary electrophoresis (CE) was performed. 
The goal was to use a different protein, bovine serum albumin (BSA), and select 
aptamers against it. BSA was used as a proof-of-principle for aptamer selection using 
CE-SELEX. 
 
1.8.3 Selection of an aptamer for I-SceI and in vivo testing 
As stated, an I-SceI induced DSB stimulates gene targeting several orders of magnitude. 




targeting molecule, with one part being an aptamer with the ability to bind to I-SceI and 
the other part being homologous to a target locus for gene correction. I-SceI would then 
target this DNA to the genomic locus to be modified. We planned to first select for I-SceI 






CONSTRUCTION AND TESTING OF A FUSION PROTEIN BETWEEN THE I-






The goal of this work was to increase the frequency of gene targeting in human cells by 
attaching the targeting DNA to a protein involved in the DSB or its repair. The concept 
was that by bringing the targeting DNA into close proximity of the DSB that it would be 
preferentially used to repair the break, thus increasing the frequency of gene targeting. In 
order to test our hypothesis, two parallel strategies were attempted. The first strategy 
involved the construction of a fusion protein between I-SceI and the GAL4 DNA-binding 
domain (GAL4-DBD).  From transient transfections in HEK-293 cells, repair was shown 
using oligonucleotides that contained the GAL4-DBD site. These targeting 
oligonucleotides were also shown to bind specifically and strongly to the GAL4-DBD 
protein in EMSA gels. Several vectors and also several yeast strains were engineered to 
contain the GAL4-DBD I-SceI fusion protein with various linkers.  Whole cell extracts 
from both yeast and HEK-293 cells did not show any expression of the fusion protein. 
 
2.2 INTRODUCTION 
2.2.1 Targeting DNA choice 
In order to carry out gene targeting, an exogenous DNA molecule must be transformed or 
transfected into the cell. There are several different targeting DNA types that could be 
used including plasmids, chromosomally integrated truncated genes, PCR products, and 
oligonucleotides. A comparison of several DNA targeting molecules (short DNA 




~2kbp) showed DNA oligonucleotides to have the highest frequency of chromosomal 
gene correction in HEK-293 cells (Nickerson and Colledge 2003). Additionally, our lab 
has sufficient experience with oligonucleotide-based gene correction in yeast and human 
cells (Storici, Durham et al. 2003). Also, oligonucleotides are relatively cheap and do not 
require time-consuming steps such as generating PCR products or isolating plasmids. For 
these reasons, we chose to use DNA oligonucleotides as our repairing DNA molecule of 
choice. 
 
2.2.2 Gene targeting assay in human cells 
We had in our possession a monoclonal cell line known as 658-D which is a derivative of 
human embryonic kidney (HEK-293) cells. The cell line contains an integrated GFP 
under the strong cytomegalovirus/chicken β actin (CMV/CBA) promoter but cannot 
express functional GFP because it is truncated by the presence of a STOP codon and the 
18 basepair I-SceI recognition site. Using this cell line, along with the corresponding 
plasmid-based assay in HEK-293 cells, we were able to detect the frequency of gene 
targeting by flow cytometry. 
 
2.3 RESULTS 




As stated, oligonucleotides were chosen as our targeting DNA molecule. After making 
this decision the question remained whether to use complementary oligonucleotides to 
form double-stranded DNA (dsDNA) or to use single-stranded DNA oligonucleotides 
(ssDNA). In yeast, it was shown that complementary DNA oligonucleotides were more 
efficient at gene targeting than either single oligonucleotide alone (Storici, Durham et al. 
2003). However, in mammalian cells there is not a clear preference for single-stranded 
oligonucleotides or double-stranded oligonucleotides but rather the preference varies 
between different mammalian systems (Lu, Lin et al. 2003, Nickerson and Colledge 
2003, Radecke, Radecke et al. 2004). In order to determine which oligonucleotide 
structure we should have chosen several transfections were done with single-stranded 
oligonucleotides, gapped duplex oligonucleotides, and fully complementary 
oligonucleotides. Gapped duplex oligonucleotides were shown to condense more than 
complementarity oligonucleotides or a 3kbp plasmid in the presence of 
poly(ethylenimine) (PEI), which is the polycationic transfection reagent that used in our 
mammalian cell transfections (Sarkar, Conwell et al. 2005). Figure 2.1 and Figure 2.2 
show the results from our studies in both a plasmid-based and chromosomal assay. It is 
clear that in both our plasmid as well as our chromosomal assay there is a strong 
preference for ssDNA over dsDNA. Interestingly, there was a strand bias in favor of 
repair with the coding strand for the chromosomal locus but no such bias existed for the 
plasmid assay. This strand bias is likely due to the chromosomal architecture at the 
integration site of GFP in 658-D. The strand bias is not likely due to cell line differences 
since the HEK-293 and 658-D cell lines are identical except for the integrated disrupted 




oligonucleotide with the 12H5 linker oligonucleotide), the majority of the molecule being 
single-stranded, the level of repair decreases significantly. This is consistent with 
previous findings in mammalian cell lines that found ssDNA oligonucleotides were a 
more favorable substrate for gene targeting in episomal or chromosomal loci compared to 
double-stranded oligonucleotides (Nickerson and Colledge 2003, Radecke, Radecke et al. 
2004). The reason for this preference is unclear but it was proposed that double-stranded 
oligonucleotides might have to unfold prior to hybridization with a target locus (Radecke, 
Radecke et al. 2004). Also, it is possible that a blunt-ended dsDNA sequence, such as that 









Figure 2.1 Comparison between complementary DNA and ssDNA in HEK-293 cells. 
Level of GFP repair following transfection with oligonucleotides to repair a 
nonfunctional GFP gene on a plasmid in HEK-293 cells. The plasmid was digested in 
vitro by I-SceI forming a DSB in GFP that could be repaired resulting in a GFP+ 
phenotype. F = oligonucleotide homologous to the coding strand of GFP (40 bases of 
homology to either side of the DSB site), R=oligonucleotide homologous to the template 
strand of GFP, and 12H5 is an oligonucleotide with 12 bases of complementarity to the 3’ 
end of the F oligo and 12 bases of homology to the 5’ end of the F oligo with a 5 base gap 









Figure 2.2 Comparison between complementary DNA and ssDNA in 658-D cells. 
Level of GFP repair following transfection with oligonucleotides to repair a 
nonfunctional GFP gene integrated somewhere in the genome along with an I-SceI 
expression vector. F = oligonucleotide homologous to the coding strand of GFP (40 bases 
of homology to either side of the DSB site), R=oligonucleotide homologous to the 
template strand of GFP, and 12H5 is an oligonucleotide with 12 bases of 
complementarity to the 3’ end of the F oligonucleotide and 12 bases of homology to the 
5’ end of the F oligonucleotide with a 5 base gap (non-complementary stretch of bases) in 






2.3.2 Plasmid design and construction 
The GAL4-DBD I-SceI fusion protein was constructed using the Clontech Matchmaker 
Yeast 2-Hybrid Assay System (Clontech, Mountainview, CA). The I-SceI coding 
sequence was PCR amplified with primers that contained BglII and SalI restriction 
enzyme sites, respectively. PCR product was digested along with the vector and the I-
SceI sequence was cloned into the multiple cloning site (MCS), downstream of the 
GAL4-DBD (Figure 2.3). After construction of the yeast vector, the GAL4-DBD and the 
GAL4-DBD I-SceI fusion protein sequences were PCR amplified and cloned into the 
pFLAG CMV 6C vector (Sigma-Aldrich) such that the fusion protein would be under the 
strong cytomegalovirus (CMV) promoter for use in mammalian cells. Additionally, 
several plasmid constructs were generated to express the GAL4-DBD or the GAL4-DBD 
fusion protein with I-SceI in the bacterial vector pMAL c4X. Bacterial plasmids 
contained the GAL4-DBD or the GAL4-DBD I-SceI fusion protein and the maltose 
binding protein (MBP) as a fusion protein. The MBP provided solubility and good 
expression of the GAL4-DBD which was subsequently purified by the Lieberman lab. 
 
The GAL4-DBD LexA-DBD fusion protein was constructed by cloning the GAL4-DBD 
sequence into the pFLAG CMV 6C vector to generate the pFLAG GAL plasmid. After 
sequencing and verification of the pFLAG GAL plasmid, the LexA-DBD sequence was 




the LexA-DBD sequence alone was cloned downstream of the GAL4-DBD and another 
construct where a flexible glycine-serine linker (GGGGS)2 was cloned in between the 






Figure 2.3 The pGBKT7 plasmid. This plasmid was used as the starting plasmid for the 
GAL4-DBD I-SceI fusion protein. The fusion protein was expressed under the strong 
constitutive yeast promoter for alcohol dehydrogenase 1a (ADH1). Also, the region 
between the GAL4-DBD and the multiple cloning site (MCS) contains the T7 promoter, a 
c-Myc epitope tag, and restriction enzyme sites. Despite this being acceptable for the 2-




2.3.3 Oligonucleotide structure design 
After determining that ssDNA oligonucleotides should be used for repair in our human 
cells instead of dsDNA oligonucleotides, each of the linkers needed oligonucleotide 
designs. For the GAL4-DBD linker strategy at least part of the oligonucleotide needed to 
be dsDNA. The GAL4-DBD binds to a 17 bp dsDNA sequence and so we needed to 
determine where on our oligonucleotide the 17 bp double-stranded DNA region should 
be. Several different DNA oligonucleotides containing the GAL4-DBD recognition 
sequence were tested for their ability to repair GFP in HEK-293 cells (and the modified 
HEK-293 cell line 658-D). The different oligonucleotides are shown in Figure 2.4. As 
stated, in our HEK-293 and 658-D cell systems, ssDNA repairs more efficiently than 
dsDNA. Therefore, the oligonucleotides generated contained only a portion of dsDNA, 
enough to contain the GAL4-DBD recognition sequence and a 5 bp spacer. It was 
discovered that oligonucleotides containing the GAL4-DBD recognition sequence at the 
5’ end of the oligo (Aa and Cc) were more efficient at repairing the DSB (Figure 2.5). 
Also it should be noted that the 658-D cell line showed a strand bias in favor of the 
repairing molecule having homology to the coding strand of GFP (hence, Aa repaired 





Figure 2.4 The different oligonucleotides tested in the HEK-293 and 658-D human 
cell lines. Each oligo pair Aa, Bb, Cc, or Dd contains the 17bp GAL4-DBD recognition 
sequence. The differences in the oligos are the positioning of the GAL4-DBD recognition 
sequence (either at the 5’ or 3’ end of the repairing oligo) and also the repairing 
sequence. For oligos Aa and Bb, the repairing sequence (GFP.F78) has homology to 39 
bases of the coding strand on either side of the DSB, whereas oligos Cc and Dd’s 







Figure 2.5 The efficiency of different oligonucleotides to accurately repair GFP by 
the DSB generated by I-SceI. The two different cell lines used are HEK-293 and 658-D 
representing both plasmid and chromosomal gene repair respectively. The F oligo is a 
single-stranded oligo that has 80 bases of homology (40b on either side of the break) to 
the GFP coding strand and the R oligo is a single-stranded oligo that has 80 bases of 
homology (40b on either side of the break) to the template strand of GFP. The other 







After determining that the optimal oligonucleotide structure for the GAL4-DBD in our 
human cells would be to contain the GAL4-DBD recognition site at the 5’ end of the 
molecule and the targeting DNA will be the coding sequence we needed to ascertain 
whether or not this molecule can still be bound by the GAL4-DBD. In order to verify the 
DNA binding capability of the GAL4-DBD to the optimal oligonucleotide structure, we 
used electophoretic mobility shift assay (EMSA) gels. EMSA works by using 
electrophoresis to separate different samples in a polyacrylamide gel. Larger, more 
positively charged samples migrate slower than smaller, more negatively charged 
samples. Initial studies were done with purified GAL4-DBD protein (confirmed by 
Western blot), and several different DNA oligonucleotides, each containing a 5’ GAL4-
DBD site, as shown in Figure 2.6. The GAL4-DBD/I-SceI fusion protein was not purified 
in the same manner so all tests for binding were done with the GAL4-DBD alone. We 
radiolabeled the different oligonucleotide designs containing the double-stranded GAL4-
DBD region and binding to the GAL4-DBD was shown with P32-labeled 
oligonucleotides containing the 17bp consensus recognition sequence. In addition to the 
GAL4-DBD recognition sequence, these oligonucleotides contained homology to GFP 
such that they could be used to restore function of the marker. Of the several initial 
oligonucleotides tested, two specific structures, the stem-loop forming single 
oligonucleotide as well as the Aa oligonucleotide mentioned previously, were chosen for 




oligonucleotide, making them ideal for use in human cells. Each of these constructs 
showed that the binding by the GAL4-DBD was specific, as excess unlabeled competitor 









Figure 2.6 The different P32-labeled oligonucleotides used in the GAL4-DBD 
EMSAs in the presence of the GAL4-DBD. The red box contains the free probe, the 
blue box contains the protein-DNA complex and the yellow box contains a super 
complex where the DNA is bound by 2 GAL4-DBD dimers. Lane 1 represents a negative 
control, a single stranded oligo that does not contain the GAL4-DBD recognition 
sequence or the spacer (the F oligo), but otherwise is homologous to the other oligos. 
Lane 2 represents another negative control, a double stranded oligonucleotide (F+R) that 
does not contain the GAL4-DBD recognition sequence. Lane 3 represents an oligo with 2 
closely spaced GAL4-DBD recognition sequences (GAL4-DBD(2)). Lane 4 represents the 
17A nucleotide along with its reverse complement (17A+RC). Lane 5 represents the stem 
loop forming oligo that contains the GAL4-DBD recognition sequence (Stem Loop). Lane 
6 represents a long single stranded oligo with a portion that is double stranded which 
contains the GAL4-DBD recognition sequence (the 17Aa oligo). Again, a schematic of 
the oligos used is on the right, the red area representing the GAL4-DBD recognition 
sequence, the orange representing a spacer and the blue region representing the GFP 




















Figure 2.7 The Stem Loop and 17Aa oligos bind GAL4-DBD. (A) the single stranded 
oligonucleotide “Stem Loop” that folds to form a small loop and a long stem which 
contains the GAL4-DBD recognition sequence and (B) the 17Aa oligo which contains a 
long single strand and short double stranded region containing the GAL4-DBD 
recognition sequence. The red boxes contain the free probes and the blue boxes contain 
the protein-DNA complexes. Lane 1 represents the condition with GAL4-DBD, the P32-
labeled oligonucleotide, and the same oligonucleotide unlabeled and in excess (a cold 
competitor to show the binding is specific). Lane 2 represents the GAL4-DBD and the 
P32-labeled oligo. Lane 3 represents the P32-labeled oligo without GAL4-DBD present. 
A schematic of the oligos used is on the right, the red area representing the GAL4-DBD 
recognition sequence, the orange representing a spacer and the blue region representing 
the GFP repairing sequence. The pink star represents the P32 label. 
  




2.3.4 in vivo testing 
The GAL4-DBD I-SceI fusion protein was tested in vivo for gene targeting stimulation. 
For the in vivo testing of the fusion protein transfections in mammalian cells as well as in 
yeast cells were performed. In the HEK-293and 658-D cell lines, transfections of the 
expression vector for the GAL4-DBD I-SceI fusion along with either of the two GAL4-
DBD site containing oligonucleotides previously tested (see Figure 2.7) did not yield any 
GFP+ (gene corrected) cells. In yeast, a strain was made in which the GAL4-DBD I-SceI 
fusion protein under the inducible GAL1-10 promoter was integrated into the TRP5 gene. 
This strain was used to compare gene correction using oligonucleotides containing the 
GAL4-DBD site or a scrambled GAL4-DBD sequence that should not be bound by the 
GAL4-DBD. In our yeast strains, double-stranded DNA oligonucleotides are more 
efficient substrates for homologous recombination than single-stranded DNA, so we were 
not limited to have only one GAL4-DBD site as was the case for studies in human cells. 
Oligonucleotides containing five tandemly repeated GAL4-DBD sites or scrambled 
GAL4-DBD sites were used as well as oligonucleotides containing only a single GAL4-
DBD or scrambled GAL4-DBD site. There was no significant difference between the 
scrambled oligonucleotides and GAL4-DBD site containing oligonucleotides for any of 
the yeast strains tested, including the original strain that did not contain the GAL4-DBD.  
 
In addition to the in vivo testing of the GAL4-DBD I-SceI fusion protein, in vitro testing 
for protein expression was performed. A plasmid expressing the GAL4-DBD under the 




The vector, pGBKT7 was previously described (see Figure 2.3). Whole cell extracts 
from the yeast strain transformed with the pGBKT7 vector were obtained using Yeast 
Protein Extraction Reagent (Y-PER) (Pierce, Rockford, IL) and Western blots were done 
using a monoclonal antibody to the GAL4-DBD (Clontech, Mountainview, CA). As can 
be seen in Figure 2.8, both the purified GAL4-DBD as well as the GAL4-DBD from the 
yeast cell extracts were able to be detected by chemiluminescence. Similarly, a plasmid 
containing the fusion protein between the GAL4-DBD and I-SceI was transformed into 
yeast. This fusion protein was generated by inserting the I-SceI coding sequence into the 
pGBKT7 vector downstream of the T7 promoter (see Figure 2.3). The whole cell 
extracts from yeast containing this plasmid do not show a detectable fusion protein of the 
GAL4-DBD and I-SceI by Western blot (see Figure 2.9). Interestingly, Western blots 
with this plasmid do show the individual GAL4-DBD, suggesting cleavage of the fusion 
protein or aberrant expression. Suspecting a problem with the linker region between the 
GAL4-DBD and I-SceI, several different plasmids and yeast strains with different linkers 
were created. As stated, the pGBKT7 plasmid does not contain a true linker sequence, but 
rather it contains a c-Myc epitope tag, followed by several restriction enzymes and the T7 
promoter. Use of a rigid proline linker (Gustavsson, Lehtio et al. 2001), a flexible 
glycine-serine linker (Zhao, Yao et al. 2008), a PRAMA linker suggested by the Doetsch 
lab Emory, as well as an alpha helix-forming linker (Zhao, Yao et al. 2008)were all 
created (the amino acid sequences are shown in Table 2.1). In addition to the GAL4-DBD 
western blots, western blots were done using a polyclonal antibody to I-SceI (Santa Cruz 
Biotechnology, Dallas, Texas) but again there was no expression seen of the fusion 




showed expression by Western blot. Additionally, changing the orientation of the fusion 
protein (such that the GAL4-DBD was at the carboxyl terminal instead of the amino 
terminal) did not improve expression. No expression was seen in yeast using a polyclonal 
antibody to I-SceI or a monoclonal antibody to the GAL4-DBD. Western blots were also 
done using extracts from HEK-293 cells transiently transfected with the GAL4-DBD and 
the I-SceI GAL4-DBD fusion protein. While there was expression detected for the GAL4-
DBD alone there was no expression detected of the fusion protein between the GAL4-


















Figure 2.8 A Western blot of purified GAL4-DBD and GAL4-DBD from a yeast 
extract. The cell extract is of a strain expressing the GAL4-DBD stably replicated under 
a 2 µm plasmid origin of replication and under the ADH1 promoter. M is the colorimetric 
molecular weight marker which does not appear on this chemiluminescent blot. Lanes 2 
and 4 are both from a yeast strain not expressing the GAL4-DBD under the ADH1 
promoter. Lanes 1 and 3 are from the yeast strain KM85 where the GAL4-DBD is 
expressed under the ADH1 promoter. Lane 5 is the positive control, purified GAL4-DBD 
from the Lieberman lab. This indicates that cell extracts expressing the GAL4-DBD can 







Figure 2.9 A Western blot of several whole cell extracts from different strains using 
a monoclonal antibody for the GAL4-DBD. E133 is the background strain for KM-85 
and KM-87 and does not contain the GAL4-DBD. The strains KM-85 and KM-87 are 
different isolates of the same strain, where the GAL4-DBD I-SceI fusion protein was 
expressed on a plasmid under the ADH1 promoter. FRO-470 is the background strain for 
PAT-5, PAT-7, and PAT-10 and should not have the GAL4-DBD. PAT-5 is FRO-470 
except the GAL4 gene has been knocked out. The PAT-7 strain contains the GAL4-DBD 
under the GAL1-10 promoter but interestingly did not show expression. PAT-10 is a 
strain where the GAL4-DBD I-SceI fusion protein (joined by a flexible glycine/serine 
(GGGGS)2 linker) is under the GAL1-10 promoter. As can be seen, none of these strains 








Linker  Sequence  Description  
pGBKT7 
“linker”  




Proline  GTPTPTPTPTGEF  Rigid linker  
Alpha-helix 
forming  





GGGGSGGGGS  Flexible linker  
PRAMA  PRAMA  Linker design 
for a fusion 
protein from the 
Doetsch lab at 
Emory  
 
Table 2.1 Sequences of different linkers for the GAL4-DBD and I-SceI fusion 
protein The table contains the sequences of the different linkers used to construct the 
GAL4-DBD and I-SceI fusion protein along with a description. The pGBKT7 vector 
contains a region between the GAL4-DBD and I-SceI but is not a true linker, hence it is 








Figure 2.10 A Western blot of several whole cell extracts from different strains using 
a polyclonal antibody for I-SceI. E133 is the background strain for KM-85 and KM-87 
and does not contain the GAL4-DBD. FRO-155 is a strain that has the I-SceI gene under 
the GAL1-10 promoter but does not have the fusion protein. The strains KM-85 and KM-
87 are different isolates of the same strain, where the GAL4-DBD I-SceI fusion protein 
was expressed on a plasmid under the ADH1 promoter. FRO-470 is the background 
strain for PAT-5, PAT-7, and PAT-10 and should not have the GAL4-DBD. PAT-5 is 
FRO-470 except the GAL4 gene has been knocked out. The PAT-7 strain contains the 
GAL4-DBD under the GAL1-10 promoter but interestingly did not show expression. 
PAT-10 is a strain where the GAL4-DBD I-SceI fusion protein (joined by a flexible 
glycine/serine GGGGS linker) is under the GAL1-10 promoter. As can be seen, none of 





In addition to the GAL4-DBD I-SceI fusion protein, we also attempted to construct a 
fusion protein between the GAL4-DBD and the LexA-DBD. The LexA-DBD is another 
well characterized, small (16 kDa) DNA binding domain responsible for binding to a 16 
bp palindromic sequence 5’ CTGTNNNNNNNNACAG 3’ (Knegtel, Fogh et al. 1995). 
For this particular set of constructs a new system was designed. Whereas in the GAL4-
DBD I-SceI fusion protein we relied on the GAL4-DBD binding to a double-stranded 
region on a small DNA oligonucleotide, for the GAL4-DBD LexA-DBD experiments we 
constructed a plasmid that contained the gene of interest flanked by LexA-DBD sites. In 
this way, our aim was to conjugate the LexA-DBD site containing plasmid targeted for 
repair with a separate plasmid that contained 200 bases of homology to the targeted gene. 
The repairing vector either had these 200 bases of homology flanked with GAL4-DBD 
recognition sites or scrambled GAL4-DBD sequences. In this way we sought to directly 
compare repair between the targeted DNA plasmid and a separate targeting DNA 
plasmid. Fusion protein constructs were made for use in our human cell lines. In this 
assay we saw no significant difference between a targeting plasmid containing the GAL4-
DBD sites and a targeting plasmid containing scrambled GAL4-DBD sites flanking the 
region of homology with either of the GAL4-DBD LexA-DBD fusion protein constructs. 
Western blots were done on mammalian cell extracts to verify expression and the GAL4-
DBD alone was detected, as was the GAL4-DBD LexA-DBD fusion protein without a 








Figure 2.11 Western blot of several whole cell extracts from HEK-293. Several whole 
cell extracts were taken after transient transfections of various plasmids. Lane 1 is a 
molecular weight marker, lane 2 and 5 are two different extracts after transient 
transfection of plasmids expressing the GAL4-DBD alone (~19 kDa), lane 3 and 6 are 
extracts after transfection with the GAL4-DBD I-SceI fusion protein, lane 4 is an extract 
after transfection with the LexA-DBD GAL4-DBD fusion protein with a flexible 
(GGGGS)2 linker between the two proteins, and lane 7 is the same plasmid except 






EMSA gels showed specific and strong binding of the GAL4-DBD by several 
oligonucleotides. The oligonucelotides shown to be capable of being bound by the GAL4-
DBD were also shown to be capable of repairing GFP in vivo. Western blots done using a 
monoclonal antibody to the GAL4-DBD, a polyclonal antibody to I-SceI, as well as a 
monoclonal antibody to the FLAG tag peptide sequence (dykddddk) did not show any 
expression of the GAL4-DBD I-SceI fusion protein. There are many potential reasons 
why the fusion protein was not expressed. As can be seen in Figure 2.9, the individual 
GAL4-DBD protein can be seen in both the strain containing the vector with the GAL4-
DBD only (KM-85) as well as strain containing the vector with the GAL4-DBD I-SceI 
fusion protein (KM-87). The presence of the GAL4-DBD alone in this strain could be the 
result of proteolytic cleavage of the linker between the two proteins. Interestingly, this 
cleavage was not seen in the Western blot using the FLAG antibody. Alternatively, the 
fusion protein may have been unstable, unable to fold properly, and/or targeted for 
degradation. 
 
Due to the inability of the GAL4-DBD I-SceI fusion protein and the GAL4-DBD LexA-
DBD to stimulate gene targeting, we opted to further develop the I-SceI DNA aptamer 
strategy. Although these particular fusion proteins, the GAL4-DBD and I-SceI along with 
the fusion protein between the GAL4-DBD and the LexA-DBD, did not stimulate gene 
targeting, without knowing the binding characteristics of the GAL4-DBD I-SceI and 




I-SceI fusion protein we cannot conclude that the concept itself was a failure. Further 
testing may yet reveal our hypothesis to be true. It also may be possible that only one of 
the two domains was able to bind DNA at any given time. Many proteins upon binding to 
their substrate undergo conformational changes and it could be that a conformational 
change in either of the domains inhibited the binding ability of the other domain. There 
are many possibilities to explain why the fusion protein strategy did not work but the 









Real-Time PCR-Coupled CE-SELEX for DNA Aptamer Selection  
 
The work presented in Chapter 3 was published as a research article under the same name 
in ISRN Molecular Biology: 
Patrick Ruff, Rekha B. Pai, and Francesca Storici, “Real-Time PCR-Coupled CE-
SELEX for DNA Aptamer Selection,” ISRN Molecular Biology, vol. 2012, Article ID 
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Aptamers are short nucleic-acid or peptide sequences capable of binding to a target 
molecule with high specificity and affinity. Also known as “artificial antibodies,” 
aptamers provide many advantages over antibodies. One of the major hurdles to 
aptamer isolation is the initial time and effort needed for selection. The systematic 
evolution of ligands by exponential enrichment (SELEX) is the traditional procedure 
for generating aptamers, but this process is lengthy and requires a large quantity of 
target and starting aptamer library. A relatively new procedure for generating 
aptamers using capillary electrophoresis (CE), known as CE-SELEX, is faster and 
more efficient than SELEX, but requires laser-induced fluorescence (LIF) to detect 
the aptamer-target complexes. Here we implemented an alternative system without 
LIF using Real Time (RT)-PCR to indirectly measure aptamer-target complexes. In 
three rounds of selection, as opposed to ten or more rounds common in SELEX 
protocols, a specific aptamer for bovine serum albumin (BSA) was obtained. The 
specificity of the aptamer to BSA was confirmed by electrophoretic mobility shift 
assays (EMSAs), an unlabeled competitor assay, and by a supershift assay. The 







Aptamers are short single-stranded oligomers made up of DNA, RNA, or peptides that 
are capable of binding a target ligand (proteins, small molecules, or even living cells) 
with high affinity. They are also known as artificial antibodies because in addition to 
binding with high affinity, they also bind with high specificity. Aptamers have several 
advantages over antibodies, including ease and low cost of production which does not 
involve animals. Aptamers are less immunogenic than antibodies and are already being 
used as therapeutic agents in humans (Singerman, Masonson et al. 2008). Nucleic acid 
aptamers also are able to act in ways that antibodies cannot. Nucleic acid aptamers, 
unlike antibodies, can be selected for and used under non-physiological conditions, such 
as high salt conditions and varying pH (Xu and Lu 2010). Also, nucleic acid aptamers are 
able to undergo specific conformational changes that antibodies cannot. For example, 
nucleic acid aptamer binding can be “turned off” by the addition of the complementary 
strand (Cao, Tong et al. 2009). Additionally, nucleic acid aptamers can undergo a 
conformational change when binding to their target, and can be used as molecular 
beacons, fluorescently “off” when unbound, and “on” when bound (Morse 2007). The 
field of aptamers is rapidly growing as is the number of applications for their use.  
Nucleic acid aptamers are “evolved” from random sequences of DNA/RNA by a process 
known as systematic evolution of ligands by exponential enrichment (SELEX) (Tuerk 
and Gold 1990)[5]. The SELEX procedure involves the use of the random library of 
DNA/RNA sequences being incubated with the target, followed by a partitioning step to 




amplification step to generate a library of sequences enriched for binding. The SELEX 
procedure generally takes months to complete, with a typical selection requiring 10 or 
more rounds before completion (Jayasena 1999). Also, traditional SELEX requires a 
support for the target (magnetic beads, membranes, etc.) to bind with. The supports 
themselves can be targets for selection, and often rounds of negative selection must be 
done to avoid aptamers for the support.  
Use of capillary electrophoresis (CE) allows for SELEX to be performed in a much 
shorter amount of time due to much more efficient partitioning and without the aptamers 
binding to the ligand support (the ligand flows freely in buffer, there is no support). In as 
little as one round of selection (Berezovski, Drabovich et al. 2005), and generally less 
than five rounds of selection, strong binding highly specific aptamers may be obtained. 
CE-SELEX is a new technology first developed for use in 2004 and has yet to be 
commonly used (Mendonsa and Bowser 2004). One of the main advantages to CE-
SELEX over traditional SELEX is that the aptamer-target complex can be detected in the 
first round of selection. This early detection contrasts traditional SELEX, where several 
rounds must be done before being able to detect any DNA (Sefah, Shangguan et al. 
2010). Most CE-SELEX is done with laser induced fluorescence (LIF) to increase the 
detection sensitivity to the analysed samples. Using CE with LIF a laser excites 
fluorescently-labeled samples passing through the glass capillary tube which then emit 
light that is captured by an on-board detector attached to the CE machine itself.  




need for an on-board laser/detector system. The system takes advantage of real-time 
polymerase chain reaction (RT-PCR). RT-PCR is able to sensitively detect DNA-target 
complexes early on in the selection procedure with an efficacy greater than that of 
traditional SELEX and equal to that of CE-SELEX with LIF. We believe that this system 
could be beneficial for researchers that have access to CE, but do not have access to CE 
with LIF, and are seeking to perform CE-SELEX. The protein that we chose to use as a 
target for aptamer selection was bovine serum albumin (BSA). 
BSA is one of the most commonly used proteins in biochemical studies. BSA is widely 
used for stabilization of enzymes, preventing enzymes of interest from adhering to tubes 
or pipettes, or as a protein comparison standard. There are several advantages to using 
BSA in that it is relatively stable, abundantly available from cow’s blood, and is of low 
cost. Due to the low cost and high abundance of BSA, we chose it to serve as the protein 
target for our RT-PCR coupled selection system. Here we report the isolation of a DNA 
aptamer with specificity for BSA using the RT-PCR coupled capillary electrophoresis 
selection system. 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Aptamer Selection 




lyophilized powder through Sigma-Aldrich and was greater than 98% pure. The BSA was 
dissolved in RB1 buffer (50 mM Tris-HCl, pH 8.2) and stored at 4 °C at a stock 
concentration of 1 mM. The RB1 buffer was also used as the run buffer for capillary 
electrophoresis. The DNA library was purchased from Alpha DNA and contained a 
sequence of 5’_CTTCTGCCCGCCTCCTTCC-(N)36-
GACGAGATAGGCGGACACT_3’ (36 random nucleotides flanked by two fixed 19 
base regions used later as primers for PCR amplification). 
The protocol for SELEX using capillary electrophoresis (CE) was essentially as 
described earlier (Berezovski, Musheev et al. 2006) but with a few modifications. The 
initial bulk affinity assay was performed with 50 µM BSA and 25 µM DNA in order to 
view any DNA-protein complexes and determine the collection window. Capillary 
electrophoresis was done using a Beckman Coulter Proteomelab PA 800 with a photon 
diode array (PDA) capable of reading wavelengths in the UV range (10 nm - 400 nm), 
separating with a voltage at 10 kV. After determination of the collection window based 
on the bulk affinity analysis, the first round of selection began. The initial in vitro 
selection procedure involved 500 nM BSA and 3.3 µM DNA. The DNA library (0.3 µl at 
100 µM) was mixed with 0.3 µl of SB3 (100 mM Tris-HCl at pH 8.2, 200 mM NaCl, and 
10 mM MgCl2) for a final concentration of 50 µM DNA library, 50 mM Tris-HCl at pH 
8.2, 100 mM NaCl, and 5 mM MgCl2. This mixture was heated in the BioRad iCycler to 
94 °C for 1 minute, and then cooled to 20 °C at a rate of 0.5 °C/second. After the folding 
of the DNA library, 5 µl of 1 µM BSA dissolved in RB1 buffer was added, and additional 
run buffer was added to make the final volume 10 µl. This brought the final 








After each round of selection, fractions were analyzed through real-time PCR (RT-PCR) 
using the ABI StepOne Plus. RT-PCR was done with two primers, the forward aptamer-
amplifying primer P1 (5’_CTTCTGCCCGCCTCCTTCC_3’) and the reverse primer P2 
(5’_AGTGTCCGCCTATCTCGTC_3’) respectively. The primers were designed using 
OligoAnalyzer (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/) to limit 
complementarity to each other, in order to decrease non-specific amplification of self-
dimerizing primers. For amplification, 20 µl of PCR mix was prepared consisting of 10 
µl of 2X Quanta SYBR Green PCR Master Mix (Roche), 0.6 µl of 10 µM P1, 0.6 µl of 
10 µM P2, 1 µl of collected fraction as template, and 7.8 µl H2O. The PCR setup is 





Table 3.1 Real-Time PCR cycling conditions 
Cycle # Denaturation Annealing Extension 
1 94 °C for 30 seconds   
2-50 94 °C for 10 seconds 55 °C for 10 seconds 72 °C for 10 seconds 
51   72 °C for 1 minute 





3.3.3 Amplification and isolation of aptamer strand 
Following RT-PCR, the fraction containing the complex was amplified using standard 
PCR. PCR was done in a 100 µl volume consisting of 1 µl of 5U/µl X-Taq polymerase 
from Takara, 3 µl of 10 µM forward primer P1, 3 µl of 10 µM reverse primer P2, 10 µl of 
10X Mg
2+
 buffer (Takara Ex Taq), 8 µl of 2.5 mM each dNTP, and 5 µl of the collected 
fraction from capillary electrophoresis. PCR was done using primer P1 and P2 as noted 
previously, except that the number of cycles for PCR amplification was based on 50% of 
the maximum yield as determined by RT-PCR. Additionally, primer P2 was biotinylated 
at its 5’ end. The biotin-labeled primer was used subsequent to PCR in order to separate 
the strand of interest and the non-aptamer strand after PCR. Magnetic beads with 
streptavidin coating from Bangs Laboratories (Biomag Streptavidin Nuclease-Free) were 
used to bind the biotin-labeled DNA. Strands were separated with 10 mM NaOH after 
three washes with wash buffer (10 mM Tris-HCl at pH 8 with 500 mM NaCl and 1 mM 
EDTA). The single-stranded aptamer pool was used in subsequent rounds of selection. 
 
3.3.4 Cloning and sequencing 
Post-selection DNA cloning of the aptamer pool was done with the TOPO Zero Blunt 
Cloning Kit (Invitrogen). Standard PCR with unlabeled primers P1 and P2 was used to 
generate double-stranded DNA containing the aptamer sequence, which was then blunt-




gene. Colonies were selected for growth on kanamycin-containing media (kanamycin 
final concentration was 40µg/mL) and plasmid DNA was isolated using the GeneJET 
Plasmid Miniprep Kit (Fermentas). Asymmetric PCR with unlabeled primers P1 and P2 
was used on the plasmid DNA to predominately generate the strand of interest which was 
then analyzed using CE and RT-PCR. 12 colonies were pooled into a group and each 
group was assayed for BSA binding using CE. Individual plasmids from each pooled 
group that showed binding were sequenced by Eurofins MWG Operon. Based on 
sequencing results, several candidate aptamers were chosen and ordered as salt-free 
oligonucleotides. Consensus sequence was analyzed using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Additionally, mFold 
(http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form) was used on each candidate 
aptamer to identify secondary structure. 
 
3.3.5 Electrophoretic Mobility Shift Assay (EMSA) 
Potential aptamer oligonucleotides and a negative control oligonucleotide were 5’ labeled 
with P32 γ-ATP using T4 Polynucleotide Kinase (New England Biolabs). The negative 
control consisted of an oligonucleotide of the same length as the random DNA library 
oligonucleotides (74 bases), contained the same flanking primer regions, and had a fixed 
sequence for its internal region 5’-
CTTCTGCCCGCCTCCTTCCGGTCGGGCACACCTGTCATACCCAATCTCGAGG 




DNA sequence generator with a specified GC content of 50% 
(http://www.faculty.ucr.edu/~mmaduro/random.htm). EMSAs were performed under 
different binding conditions. The binding conditions for the initial EMSA were done by 
adding equal amounts of SB3 buffer to the labeled oligonucleotides (20,000 cpm 
equivalent) and incubating at 94 
o
C for 1 minute in a PCR machine and a quick chilling 
to 20 
o
C at a rate of 0.5 
o
C per second (total time taken is ~4 minutes). BSA stock of 1 
mM was made in RB1 buffer (the run buffer used in the CE-SELEX protocol). Different 
dilutions of BSA as required for assessing aptamer binding were also made in RB1 
buffer. With fixed concentration of the γP32-labeled candidate aptamer, the concentration 
of the ligand (BSA) was varied from 50 to 800 µM. 
The buffer used for binding was a 6X buffer consisting of 600 mM ammonium chloride, 
300 mM potassium chloride, 30 mM sodium chloride, 120 mM Tris-HCl pH 7.5, 30% 
glycerol, and bromophenol blue (BPB) 0.25%. The entire binding conditions were made 
up to 10 µl with RB1 buffer. The reaction was incubated at room temperature for 30 
minutes, after which 1.5 µl of 10X loading buffer (200 mM Tris-HCl pH8.2, 50% 
glycerol, and BPB 0.25%) was added and the reaction was left on ice for 5-15 minutes 
before loading into the gel. The reaction complex was run on an 8% polyacrylamide gel 
under non-denaturing conditions. Mini-gels were made with stock solutions of 40% 
acrylamide/bis-acrylamide (29:1), 1X Tris-borate EDTA (TBE), 10% ammonium 
persulfate (APS), and tetramethylethylenediamine (TEMED). Gels were run using the 
Mini-PROTEAN Tetra Cell apparatus from BioRad. Pre-run was done in 1X TBE buffer 
for 1 hour prior to loading of the samples. The samples were run at 150 V until the 




analyzed by Phosphor Imager (Molecular Dynamics – Typhoon Trio Imager). After the 
initial EMSA, binding conditions were slightly changed. Apart from the above mentioned 
6X buffer, an additional 5X binding buffer containing 100 mM Tris-HCl pH 8.5, 250 mM 
NaCl, 10 mM MgCl2, 10 mM ZnCl2, and 10% glycerol was added in the incubation 
mixture. Furthermore, the radio-labeled oligonucleotides were added directly to the 
incubation mixture and not heated to 94
 o
C as done previously. Lastly, the incubation was 
carried out at room temperature for 1 hour and 30 minutes, after which the samples were 
left on ice for 5-15 minutes on the 4% non-denaturing gels which were pre-run for 1 hour 
in 1X TBE as described above. 
 
3.3.6 Competition assays 
Increasing concentrations of the specific unlabeled oligonucleotide was added during 
incubation of the ligand (BSA)-aptamer complex (conditions described above). Three 
different amounts (1.25, 2.5, and 5 pmol) were used. Complex formation was allowed to 
go on for 30 minutes at room temperature before the radioactively-labeled 
oligonucleotide was added and the incubation was continued for another hour and 30 
minutes. In the control sample all the conditions were similar except for the absence of 
the unlabeled competing oligonucleotide.  
 





EMSAs were set up using 4 µg of the anti-BSA polyclonal antibody (obtained from 
Invitrogen). Essentially, the antibody (4 µg) was mixed with BSA (500 µM) along with 
the 5X binding buffer and left on ice for 1 hour. The radioactively-labeled I1-5 aptamer 
and the 6X buffer were added next and the incubation continued for 1 hour and 30 
minutes at room temperature before stopping the incubation by leaving the samples on 




3.4 RESULTS AND DISCUSSION 
 
3.4.1 CE machine calibration and initial runs 
The general scheme of RT-PCR coupled CE-SELEX is shown in Figure 3.1. To test the 
concept that aptamer selection with CE-SELEX and RT-PCR could be feasible, we first 
began by calibrating the capillary electrophoresis (CE) machine. The CE machine used, 
the Proteomelab PA 800, is incapable of running solutions that contain high 
concentrations of salts. Due to this limitation, our buffers had to be tested to find the 
proper salt balance to ensure that the machine did not fail but at the same time have 
enough salt to stabilize our aptamer structures. Therefore the buffer condition used for the 
initial step of folding the DNA library was done in a high salt buffer (50 mM Tris-HCl at 
pH 8.2, 100 mM NaCl and 5 mM MgCl2), followed by incubation and running the folded 
DNA library in low salt concentrations (50 mM Tris-HCl at pH 8.2, 6 mM NaCl, and 300 
nM MgCl2) to ensure both proper folding and running of the DNA library. Although the 
low salt problem may have excluded many potential binders to BSA, low salt 
concentrations actually mirror the physiological conditions more accurately since the 
cellular level of magnesium is only ~1-2 mM (Carothers, Goler et al. 2010). After 
optimizing for the salt concentrations we used CE and ran a large amount (100 µM) of 
BSA alone in order to visualize the free protein peak run timing. Next we performed the 






Figure 3.1 Summary of RT-coupled CE-SELEX The overall scheme of the protocol 
for selection is laid out sequentially. The scheme omits the steps after selection of the 
aptamers. Further analysis may be carried out to confirm the specificity and affinity of 







3.4.2 Bulk affinity analysis and selection 
Once the individual free protein and free DNA run times were established, we proceeded 
to combine BSA and DNA for a bulk affinity analysis Figure 3.2. The bulk affinity 
analysis allowed us to visualize peaks for the free BSA and the free DNA in combination, 
and this information was used to determine the collection window. The CE machine used 
was the Proteomelab PA 800 from Beckman Coulter, which did not have laser-induced 
fluorescence (LIF). To sensitively detect protein-DNA complexes between the free DNA 
and free protein, we relied on RT-PCR. The collection window started from the end of 
the free protein peak to the start of the free DNA peak Figure 3.3. This collection 
window was further subdivided into seven separate two-minute fractions. The seven 
fractions, instead of just one fraction, allowed us to analyze with greater precision the 
region of the DNA-protein complex. In the first round of selection the concentration of 
BSA was reduced to 500 nM in order to increase the stringency of selection. In the first 
round of selection the initial collected fraction of DNA detected by RT-PCR needed36 
cycles of amplification to reach 50% of the maximum yield, the midpoint cycle, of PCR 
Figure 3.3. The second fraction analyzed had a higher amount of DNA compared to the 
first fraction collected, taking only 34 cycles of amplification to reach the midpoint cycle. 
The amount of DNA collected for the third and fourth fractions was lower than that of the 
second fraction collected. The fifth fraction collected showed a marked increase in DNA 
indicative of the beginning of the free DNA peak and so this fraction was not used. The 




fraction collected since this fraction was collected by CE after the free protein peak, but 






Figure 3.2 Bulk affinity assay of BSA and DNA This electropherogram is the bulk 
affinity assay in which a high concentration of BSA (100 μM) and DNA (3 μM) was run 
together. The y-axis represents the absorbance at 280 nm, and the x-axis is the run time to 
the absorbance detector. The tall peak starting around 40 minutes is the free BSA, and the 
smaller peak starting around 77 minutes is the free DNA. The collection window for the 









Figure 3.3 CE fractions collected and analyzed (a) The time points at which the seven 
fractions were collected during the first round of CE selection are represented by the bars 
in the graph. The x-axis for the bar graph and the electropherogram is the run time to the 
absorbance detector in minutes. The y-axis of the electropherogram represents the 
absorbance at 280 nm. The y-axes for the bar graphs are the number of RT-PCR cycles it 
took to reach 50% of the maximum or the midpoint cycle. The earlier the fraction reached 
the midpoint, the more DNA the fraction contained. The electropherogram above the bar 
graph is shown as a guide since the actual amount of BSA used for round 1 of selection is 
very low and it cannot be detected by CE. A supposed complex was detected in the 
second fraction collected during round 1 of selection (white bar). The supposed complex 
in the 2nd fraction of round 1 was analyzed in two test rounds using 100 μM BSA (b) or 
no BSA (c). Seven fractions were collected at the same time points as the seven fractions 
shown in (a) and the corresponding RT-PCR bar graphs of the midpoints are shown, with 




The collected DNA containing the supposed DNA-protein complex was RT-PCR 
amplified using primers flanking the internal random sequence. The forward primer, P1, 
amplified the aptamer-containing strand of interest, while the reverse primer, P2, 
amplified the non-aptamer complementary strand. In a previous protocol to select DNA 
aptamers, it was shown that over-amplification of the random library leads to formation 
of non-specific products (Berezovski and Krylov 2005), therefore the random library was 
only amplified to ~50% of the maximum yield as measured by RT-PCR. After RT-PCR 
analysis revealed the optimum number of cycles to amplify the collected DNA, a regular 
PCR using more of the collected DNA was performed. In this regular PCR, the P2 primer 
was labelled at its 5’ end with biotin while P1 had no modifications. After the PCR, the 
DNA products were attached to streptavidin-coated beads due to the strong interaction 
between the streptavidin on the beads and the biotin-labelled primer P2. After 
immobilization on the beads and several washing steps, the forward aptamer-containing 
strand was released from the complementary strand by incubation with 10 mM NaOH. 
After this step, the binding of the new aptamer pool was analyzed using CE and RT-PCR. 
To assess the binding of the newly generated aptamer pool to the target, two separate CE 
runs were done, one with a 200-fold molar excess of BSA used for the first round of 
selection (100 µM) (Figure 3.3) and another without any BSA (Figure 3.3). Based upon 
these CE test runs it was clear that the second fraction collected in round one of CE-
SELEX did show binding to BSA. The aptamer pool (5 µl of the collected fraction) was 
then subjected to another round of selection. Selection continued until the fourth round, at 
which point RT-PCR did not show any change in the amount of DNA at the complex and 





3.4.3 Post-selection characterization of potential aptamers 
Potential aptamers collected during the third round of selection were again amplified and 
then used for cloning. Instead of amplifying with a biotin-labelled P2 primer, the 
potential aptamers were amplified with a non-labelled P2 primer since the biotin label at 
the 5’ end of the DNA might interfere with ligation during cloning. TOPO blunt-end 
cloning was performed with the aptamer pool and colonies were selected by growth on 
LB plus kanamycin plates. Two hundred colonies were selected and analyzed for BSA 
binding using CE and RT-PCR. Groups of 12 colonies were combined in order to 
facilitate faster analysis. In order to amplify the aptamer strand from the vector with the 
aptamer insert, asymmetric PCR was performed using a 10-fold excess of the aptamer 
strand primer. Four groups, I1, R2, G2, and O3 showed stronger binding than the others 
by RT-PCR and then the individual clones from these groups were sequenced.  
After sequencing, in order to confirm that the potential aptamer sequences were binding 
to BSA, salt-free oligonucleotides containing the potential aptamer sequences were used 
in EMSA gels. EMSAs work on the principle that DNA bound in a DNA-target complex 
will run slower than free DNA. The free DNA will appear at the bottom of the gel, while 
the DNA bound in the DNA-target complex will be shifted higher up in the gel. The 
potential aptamers, as well as a negative control (described in Materials and Methods), 
were initially screened with a set of binding conditions similar to that of the CE 
experiments. Only those sequences that were 76 or 75 bases in length, and identical or 




subsequently screened by EMSA. The candidate aptamer sequences were analyzed in 
silico by using ClustalW2 and mFold, but no consensus sequence or specific secondary 
structure between the sequences was found. 
Of the initial group of oligonucleotides screened by EMSA, the I1 group, one member of 
this group of potential aptamers, I1-5, did bind to BSA and a distinct bound complex 
could be visualized at 500 and 800 µM BSA in the initial EMSA (Figure 3.4). The bound 
complex showed a modest, but distinct shift. Also in the initial EMSA, at higher 
concentrations of BSA (>500 μM), a faint band could be seen. This band was considered 
a nonspecific complex because both the negative control and the I1-5 aptamer had this 
band. In this EMSA, and in all subsequent EMSAs, the appearance of radio-labeled DNA 
at the top of each lane, in the well, can be seen. The DNA at the top of the lanes is caused 
due to the single-stranded nature of the DNA. The single-stranded DNA is capable of 
forming aggregates with itself and with the loading dye. The size of these aggregates 
prevents the DNA from entering the gel and thus it remains in the well. After the initial 
EMSA modeled after the CE experiments, binding conditions were changed to include 
higher salt conditions that were not possible to run with the Proteomelab PA 800. These 
higher salt conditions were used to stabilize the aptamer secondary structure. In addition 
to buffer conditions, we also did not subject the aptamers to the heating at 94 ºC prior to 
incubation. Again the potential aptamer I1-5 showed a bound complex using these 
modified binding conditions (Figure 3.4). After the initial screen for potential aptamers 
with the I1 group, a subsequent screen using oligos from the G2 group and the modified 
EMSA conditions revealed several additional aptamers for BSA (Figure 3.5). The list of 













Figure 3.4 Confirmation of CE-SELEX aptamer selection by EMSA (a) Shown is the 
initial EMSA done with the BSA aptamer, I1-5, selected through RT-PCR coupled CE-
SELEX, along with a negative control of the same length (“C” in the figure) described in 
Section 2. At 500 μM BSA a specific complex, formed between the BSA and DNA. Also, 
there is a higher band corresponding to nonspecific interaction at high concentrations of 
BSA in both the negative control and the aptamer I1-5 sequences. (b) EMSA of I1-5 and 
negative control with the modified binding conditions. The binding pattern was the same 








Figure 3.5 EMSA gel confirming binding of group G2 aptamers Shown is a screen 
done with potential aptamers from the second group tested, G2. Several from this group 
were capable of binding to BSA. I1-5 was used as a positive control for binding, and the 








Table 3.2 Sequences of potential aptamers for BSA The table contains the sequences 
of the potential aptamers from each of the pooled groups of clones that showed binding to 
BSA by RT-PCR analysis. These sequences were ordered as salt-free oligonucleotides 
and analyzed using electrophoretic mobility shift assays (EMSAs), and sequences that 





3.4.4 Further characterization of I1-5 aptamer 
Only the I1-5 oligonucleotide was further pursued as it was the first aptamer discovered 
by the screen that consistently showed binding ability to BSA in the CE-SELEX as well 
as under the two different EMSA conditions. To further confirm the specificity of this 
aptamer to BSA, a supershift assay using an antibody to BSA was performed. In the 
presence of 4 µg of the anti-BSA polyclonal antibody, the binding capacity was reduced 
as seen by an appreciable reduction in the intensity of the radioactive oligo banding 
pattern (Figure 3.6). This supports the idea that the anti-BSA polyclonal antibody and the 
BSA aptamer I1-5 recognize the same epitope. A similar pattern of banding was reported 
for the human neurofilament mRNA binding to superoxide dismutase1 (SOD1) in a 
supershift assay (Ge, Wen et al. 2005). Also, competition assays were performed by 
incubating BSA with an excess of unlabeled I1-5 aptamer of three different amounts 
(1.25, 2.5, and 5 pmoles) before the addition of the labeled I1-5, the BSA-aptamer bound 
complex was abolished in the presence of higher amounts of the unlabeled competitor 
(Figure 3.7). Although by EMSA the I1-5 aptamer showed low binding affinity to BSA, 
the cold-competitor assay, as well as the supershift assay indicated a specific interaction 
was occurring between BSA and the I1-5 aptamer, thus supporting the effectiveness of 






Figure 3.6 Supershift assay with inclusion of antibody to BSA binding in gel 
retardation assays A polyclonal antibody to BSA was tested for binding to BSA in the 
reaction complex and analyzed by EMSA. The negative control previously shown not to 
bind to BSA was used as well as I1-5, the BSA aptamer. For the negative control, no 
binding to BSA was seen at 100 μM or 500μM BSA (lane 2 and 3). With addition of 4 μg 
of the antibody, there was some nonspecific binding, as seen by the faint band, by the 
control sequence (lane 4). However, with I1-5 there was binding to 500 μM BSA (lane 7), 
but this binding was disrupted when the antibody was incubated with BSA prior to the 
EMSA (lane 8). As stated previously, some of the radiolabeled DNA formed aggregates 
incapable of entering the gel, giving rise to the bands at the top of the lanes. A slight leak 
occurred during gelling such that the top of lane 8 appears disjointed due to the shape of 





Figure 3.7 Competition assay with unlabeled I1-5 aptamer Unlabeled “cold” I1-5 
aptamer at 0, 1.25, 2.5, and 5 pmol as indicated were incubated with 500 μM BSA 
(indicated by the “+”) before addition of the P32-labeled I1-5 (represented by a star) 
aptamer. Again, the formation of DNA aggregates is present at the top of the lanes. As 
unlabeled DNA competitor increases, the amount of radiolabeled DNA trapped in the 






The conclusion drawn from our studies is that we have been able to generate an aptamer 
for BSA with appreciable specificity in a few rounds of selection from a random library 
of DNA oligonucleotides.  
The protocol described here is very efficient compared to the traditional SELEX which 
takes much more time and reagents. As noted previously, traditional SELEX makes use 
of a solid support to which the target must be bound. The coupling of the target to the 
support is not completely efficient and often much of the target remains unbound and 
washed away. Using CE-SELEX there is no need for a solid support and because of the 
small size of the capillary, a much smaller amount of target is required. Even though CE-
SELEX is much more efficient than traditional SELEX, CE-SELEX still requires 
additional equipment (LIF) beyond the standard capillary electrophoresis machine. CE is 
not restricted to the isolation of aptamers, and while many labs may have a CE machine, 
much fewer will have one with LIF. Our system can be used with any CE machine, with 
or without LIF. 
Another advantage of the system is the high level of sensitivity. RT-PCR and LIF both 
work under the principle of fluorescence. While LIF can very sensitively detect DNA-
target complexes directly, RT-PCR has the potential to be more sensitive because unlike 
LIF which directly detects the fluorescent signal, RT-PCR can amplify the signal. By 
amplifying a signal undetectable by LIF, DNA-target complexes that would have been 
missed by LIF could be detected and collected using our system. Taken together, the 




CE-SELEX with RT-PCR described here can benefit other researchers that are also 
interested in selecting for aptamers and would like to use CE-SELEX, but are unable to 
do so for lack of LIF. 
BSA was chosen to test our RT-PCR coupled selection system, but the BSA aptamer we 
selected may be beneficial itself. Due to the high amount of BSA used in many 
biochemical assays, sometimes the amount of BSA present in a mixture of proteins 
obscures accurate readings of proteins of interest. It would be useful to have a way to 
deplete this unwanted BSA from a reaction. Also, BSA can be allergenic (Natale, Bisson 
et al. 2004) and in certain situations it might be beneficial to detect small amounts of 
BSA contaminant present in cow’s milk. Currently antibodies to BSA provide an answer 
to these issues, but as previously mentioned there are several advantages to using 
aptamers over antibodies. 
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PROTEIN-ASSISTED TARGETING OF GENES BY A DNA APTAMER TO I-
SCEI 
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DNA aptamers are sequences of DNA selected for their ability to bind a specific target. 
We selected a DNA aptamer to the I-SceI endonuclease, which binds an 18-bp DNA 
sequence and generates a DNA double-strand break (DSB). Bifunctional oligonucleotides 
containing the I-SceI aptamer sequence or a non-binding control of equal length were 
generated as part of a longer DNA molecule that contained a sequence tract with 
homology to repair the I-SceI generated DSB in the chosen genomic locus. The aptamer 
portion binds I-SceI which effectively targets the entire DNA molecule to the site of the 
break. In yeast the I-SceI aptamer stimulated gene targeting two to fifteen-fold over the 
non-binding control. In addition to the work in yeast, correcting DNA oligonucleotides 
containing the I-SceI aptamer sequence were used for gene targeting in human cells and 
showed stimulation of gene targeting two to sixteen-fold over the control 
oligonucleotides. Taken together, this work provides a novel strategy to increase gene 







Targeted gene modification in human cells would be a powerful tool for researchers 
interested in functional analysis of genes as well as patients suffering from genetic 
disorders. The primary limitation of gene targeting is the low frequency with which it 





 treated cells(Vasquez, Marburger et al. 2001). The low frequency of gene targeting, 
which relies on homologous recombination (HR), is due in part to the much higher 





 treated cells(Vasquez, Marburger et al. 2001). HR and NHEJ are the two 
major pathways known to repair a DNA double-strand break (DSB), which if left 
unrepaired is lethal to the cell. NHEJ joins the two ends of the DSB in a sequence 
independent manner and can even insert foreign DNA at the site of a DSB in a process 
known as random integration. Random integration by its nature results in unpredictable 
outcomes, which can include cis or trans-activation of a gene downstream of where the 
transgene was inserted, disruption of regulatory elements, or creation of aberrant fusion 
proteins all of which could lead to diseases such as cancer(Kohn, Sadelain et al. 2003). 
Gene targeting, in which a sequence homologous to the DNA at the DSB is used to repair 
the DSB, offers a safer and more precise means to integrate a gene of interest or modify 
an existing gene. 
As stated, the level of spontaneous gene targeting is low, but there are several strategies 
used to increase the frequency of gene targeting. It was shown that a DSB at the target 




bacteria(Nussbaum, Shalit et al. 1992), yeast(Storici, Durham et al. 2003), plants(Puchta, 
Dujon et al. 1993), fruit flies(Banga and Boyd 1992), mice(Rouet, Smih et al. 1994), 
human embryonic stem cells(Smih, Rouet et al. 1995), and many other cell types. 
Another strategy to increase gene targeting in mammalian cells has been achieved 
through the overexpression of key recombination proteins from HR proficient organisms. 
Overexpression of bacterial RecA led to a 10-fold increase in gene targeting in mouse 
cells(Shcherbakova, Lanzov et al. 2000), likewise overexpression of yeast Rad52 led to a 
37-fold increase in gene targeting in human cells(Di Primio, Galli et al. 2005). 
Conversely, another strategy for increasing gene targeting in human cells involves 
decreasing the amount of the DSB repair through the pathway of NHEJ. In mouse 
embryonic stem cells an increase in gene targeting was seen in Ku70 (6-fold), XRCC4 
(2-fold), and DNAPK-cs (2-fold) deficient cell lines(Pierce, Hu et al. 2001) and a 3-fold 
increase in Chinese hamster ovary cells lacking DNAPK-cs(Allen, Kurimasa et al. 2002). 
Similarly, knockdown of KU70 and XRCC4 in human colon cancer cells lead to a 30-
fold increase in gene targeting(Bertolini, Bertolini et al. 2009). 
Different from the strategies mentioned above focused on increasing HR or decreasing 
NHEJ, it was shown that by knocking down human SMC1, important for HR, gene 
targeting increased(Potts, Porteus et al. 2006). The sister chromatid is the normal donor 
DNA for HR repair, but in the case of gene targeting an exogenous DNA acts as the 
donor for repair. HR with the sister chromatid actually hinders gene targeting by 
exogenously introduced DNA. By knocking down hSMC1 which is required for sister 
chromatid HR, gene targeting increased four-fold. hSMC1 and hSMC3 form the cohesin 




other during a DSB. Without close proximity to the DSB site the sister chromatid was 
used less frequently as a donor, shifting repair of the DSB more toward HR with the 
exogenous sequence (gene targeting). 
We have developed a novel delivery system, which we call protein-assisted targeting, to 
increase gene targeting by guiding the exogenous DNA to the site of modification. The 
system is designed to increase gene targeting by increasing the amount of exogenous 
DNA available at the target site, while simultaneously reducing random integration of 
exogenous DNA outside of the target. By tethering the exogenous DNA to the site-
specific homing endonuclease I-SceI, we achieve targeted delivery of exogenous DNA to 
the site of the DSB (Figure 4.1). DNA aptamers were selected for I-SceI using a variant 
of capillary electrophoresis systematic evolution of ligands by exponential enrichment 
(CE-SELEX) called “Non-SELEX” (Berezovski, Musheev et al. 2006). DNA aptamers 
are sequences of DNA that because of their unique secondary structure are able to bind to 
a specific target with high affinity. By synthesizing a DNA oligonucleotide that contained 
the aptamer sequence as well as homology to restore the DSB, we were able to increase 
gene targeting frequencies two to fifteen-fold over a non-binding control in yeast and two 
to sixteen-fold over a non-binding control in human cells. Our strategy offers a novel way 










Figure 4.1 Protein-assisted targeting model (for yeast TRP5) Above is the model for protein-assisted targeting in yeast. Briefly, 
oligonucleotides containing the ISB7 aptamer along with a region of homology to restore the TRP5 gene are transformed into the cell. 
Simultaneously to the oligonucleotide transformation, the I-SceI gene under the GAL1-10 promoter is expressed. The ISB7 aptamer 
then binds to the I-SceI protein, which shuttles the oligonucleotide into the cytoplasm. I-SceI drives the oligonucleotide to the TRP5 




4.3 MATERIALS AND METHODS 
4.3.1 Aptamer Selection   
The target protein of interest, I-SceI, was kindly provided by Dr. Frederick Gimble in 
storage buffer (10mM KPOi pH 7.4, 100nM EDTA, 1mM DTT, 100mM NaCl, and 50% 
glycerol). Prior to selection, in order to remove storage buffer components, I-SceI was 
dialyzed. I-SceI was dialyzed in Run Buffer 1 (RB1), 50 mM Tris-HCl at pH 8.2, 
yielding a concentration of 3 µM I-SceI in RB1 post dialysis. RB1 was the run buffer 
used for the capillary electrophoresis. The DNA library was purchased from Alpha DNA 
(Montreal, Quebec) and contained a sequence of  
5’_CTTCTGCCCGCCTCCTTCC-(N)36-GACGAGATAGGCGGACACT_3’ (36 
random nucleotides flanked by two fixed 19 base regions used later as primers for PCR 
amplification). 
The protocol for SELEX using capillary electrophoresis (CE) was essentially as 
described earlier [10] but with a few modifications. Initial calibrations were done with a 
serial dilution of the aptamer library in RB1. The initial bulk affinity assay was 
performed with 1.5 µM I-SceI and 100 nM DNA in order to view any DNA-protein 
complexes and determine the collection window. Capillary electrophoresis was done 
using a Beckman Coulter P/ACE MDQ with laser-induced fluorescence (LIF) detection. 
The LIF was composed of a 488 nm air-cooled argon ion laser along with an on-board 
detector. Separation was carried out with a voltage of 10 kV. After determination of the 
collection window based on the bulk affinity analysis, the first round of selection began. 




DNA. The DNA library (5 µl at 100 µM) was mixed with 5µl of SB3 (100 mM Tris-HCl 
at pH 8.2, 200 mM NaCl, and 10 mM MgCl2) for a final concentration of 50 µM DNA 
library, 50 mM Tris-HCl at pH 8.2, 100 mM NaCl, and 5 mM MgCl2. This mixture was 
heated in the BioRad iCycler to 94 °C for 1 minute, and then cooled to 20 °C at a rate of 
0.5 °C/second. After the folding of the DNA library, 5 µl of 200 nM I-SceI dissolved in 
SB1 buffer (50 mM Tris-HCl at pH 8.2, 100 mM NaCl, and 5 mM MgCl2) was added to 
make the final volume 10 µl. This brought the final concentrations to 50 µM DNA 
library, 100 nM I-SceI, 100 mM NaCl, 5 mM MgCl2, and 50 mM Tris-HCl (pH 8.2). The 
collection window was from the beginning of the first complex peak to the end of the last 
complex peak, well before the free DNA peak. The fraction collected was typically 0.3 µl 
to 0.5 µl which was collected into a tube containing 10 µl of the above mixture except 
without any additional DNA. After 15 minutes of incubation at room temperature, this 
new mixture was used in subsequent rounds of selection. Two additional rounds of 
selection proceeded in this manner. 
4.3.2 qRT-PCR 
After the aptamer selection, the collected fractions containing the aptamer pools were 
analyzed through quantitative real-time PCR (qRT-PCR) using the ABI StepOne Plus. 
qRT-PCR was done with two primers, the forward aptamer-amplifying primer P1 
(5’_CTTCTGCCCGCCTCCTTCC_3’) and the reverse primer P2 
(5’_AGTGTCCGCCTATCTCGTC_3’) respectively. The primers were designed using 
OligoAnalyzer (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/) to limit 




dimerizing primers. For amplification, 20 µl of PCR mix was prepared consisting of 10 
µl of 2X Quanta SYBR Green PCR Master Mix (Roche), 0.6 µl of 10 µM P1, 0.6 µl of 
10 µM P2, 1 µl of collected fraction as template, and 7.8 µl H2O. The PCR setup is 




Table 4.1 Real-Time PCR cycling conditions 
Cycle # Denaturation Annealing Extension 
1 94 °C for 30 seconds   
2-50 94 °C for 10 seconds 55 °C for 10 seconds 72 °C for 10 seconds 
51   72 °C for 1 minute 






4.3.3 Amplification and isolation of aptamer strand 
Following qRT-PCR, the fraction containing the potential aptamers was amplified using 
standard PCR. PCR was done in a 100 µl volume consisting of 1 µl of 5U/µl X-Taq 
polymerase from Takara, 3 µl of 10 µM forward primer P1, 3 µl of 10 µM reverse primer 
P2, 10 µl of 10X Mg
2+
 buffer (Takara Ex Taq), 8 µl of 2.5 mM each dNTP, 70 µl H2O 
and 5 µl of the collected fraction from capillary electrophoresis. PCR was done using 
primer P1 and P2 as noted previously, except that the number of cycles for PCR 
amplification was based on 50% of the maximum yield as determined by qRT-PCR. 
Additionally, primer P2 was biotinylated at its 5’ end. The biotin-labeled primer was used 
subsequent to PCR in order to separate the strand of interest and the non-aptamer strand 
after PCR. Magnetic beads with streptavidin coating from Bangs Laboratories (Biomag 
Streptavidin Nuclease-Free) were used to bind the biotin-labeled DNA. Strands were 
separated with 10 mM NaOH after three washes with wash buffer (10 mM Tris-HCl at 
pH 8 with 500 mM NaCl and 1 mM EDTA). The single-stranded aptamer pool was used 
in subsequent cloning. 
4.3.4 Cloning and sequencing 
Post-selection DNA cloning of the aptamer pool was done with the TOPO Zero Blunt 
Cloning Kit (Invitrogen). Standard PCR with unlabeled primers P1 and P2 was used to 
generate double-stranded DNA containing the aptamer sequence, which was then blunt-




gene. Colonies were selected for growth on kanamycin-containing media (kanamycin 
final concentration was 40µg/mL) and plasmid DNA was isolated using the GeneJET 
Plasmid Miniprep Kit (Fermentas). Plasmid DNA was crudely extracted by placing 
selected colonies into 50 µL of RNAse/DNAse-free H2O and incubated in a boiling water 
bath for 5 minutes. Debris was pelleted by centrifugation for 10 minutes at 10,000 X g 
and supernatant was used for an asymmetric PCR. Asymmetric PCR with 5 µL unlabeled 
primers P1 and P2 were used on the plasmid DNA to predominately generate the strand 
of interest which was then analyzed using CE with LIF. PCR product was used with 1.5 
µM I-SceI in the same manner described previously. Individual plasmids that showed 
strong binding through asymmetric PCR product were sequenced by Eurofins MWG 
Operon. Based on sequencing results, several candidate aptamers were chosen and 
ordered as salt-free oligonucleotides. Consensus sequence was analyzed using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Additionally, mFold 
(http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form) was used on each candidate 
aptamer to identify secondary structure. 
4.3.5 Electrophoretic Mobility Shift Assay (EMSA) 
Potential aptamer oligonucleotides and a negative control oligonucleotide were 5’ labeled 
with P32 γ-ATP using T4 Polynucleotide Kinase (New England Biolabs). The negative 
control consisted of an oligonucleotide of the same length as the random DNA library 
oligonucleotides (74 bases), contained the same flanking primer regions, and had a fixed 





CCAGACGAGATAGGCGGACACT-3’. The internal region was chosen using a random 
DNA sequence generator with a specified GC content of 50% 
(http://www.faculty.ucr.edu/~mmaduro/random.htm). I-SceI was dialyzed before running 
the EMSA gels in Run Buffer 1 (RB1), 50mM Tris-HCl at pH 8.2, as previously 
described. Bovine serum albumin (BSA) was purchased as a lyophilized powder through 
Sigma-Aldrich and was greater than 98% pure. BSA stock of 10 mg/mL was made in 
RB1 buffer. 
Equal amounts of SB3 (100 mM Tris-HCl at pH 8.2, 200 mM NaCl, and 10 mM MgCl2) 
and γP32-labeled DNA were added together for a final concentration of 50 mM Tris-HCl 
at pH 8.2, 100 mM NaCl, and 5 mM MgCl2. Labeled oligonucleotides and SB3 were 
incubated at 94 
o
C for 1 minute in a PCR machine and a quick chilling to 20 
o
C at a rate 
of 0.5 
o
C per second (total time taken is ~4 minutes). 
The buffer conditions used for binding had several components. Each reaction consisted 
of 2 µL 5X EMSA buffer 1 (100 mM Tris-HCl at pH 8.5, 250 mM NaCl, 10 µM ZnCl2, 
10 mM MgCl2, 10% glycerol), 1 µL BSA (10 mg/ml), 1 µL freshly prepared 20 mM 
DTT, and 1 µL 100 mM MgCl2 for a final buffer concentration of 20 mM Tris-HCl, 50 
mM NaCl, 2 µM ZnCl2, 22 mM MgCl2, 1mg/mL BSA, 4 mM DTT, and 2% glycerol. 
After mixing these components together, 2 µL of dialyzed I-SceI (3 µM) for each reaction 
was added, bringing the volume to 7 µL. Reactions were aliquoted and 0.5 µl to 1 µl 
(20,000 cpm equivalent) of γP32-labeled oligonucleotides were added. The reaction 
mixture of DNA and I-SceI was incubated for 30 minutes at room temperature. After 




NaCl, 300 mM KCl, 30% glycerol, 0.25% bromophenol blue) was added bringing the 
final buffer concentration to 44 mM Tris-HCl, 1mg/mL BSA, 4 µM ZnCl2, 160 mM 
NaCl, 120 mM NH4Cl, 60 mM KCl, 14 mM MgCl2, 2 mM DTT, 10% glycerol, 0.05% 
bromophenol blue, and 600 nM dialyzed I-SceI. After addition of EMSA buffer 2 the 
samples were put on ice until being loaded into the gel. The reactions were run on 4% 
polyacrylamide gels under non-denaturing conditions. Mini-gels were made with stock 
solutions of 40% acrylamide/bis-acrylamide (29:1), 1X Tris-borate EDTA (TBE), 10% 
ammonium persulfate (APS), and tetramethylethylenediamine (TEMED). Gels were run 
using the Mini-PROTEAN Tetra Cell apparatus from BioRad. Pre-run was done in 1X 
TBE buffer for 1 hour prior to loading of the samples. The samples were run at 150 V 
until the bromophenol blue dye reached the bottom of the gel. The radioactivity in the gel 
was analyzed by Phosphor Imager (Molecular Dynamics – Typhoon Trio Imager).  
4.3.6 Human cell lines, plasmids, and procedures 
Human embryonic kidney (HEK-293) cells were grown in Dulbecco’s modified Eagle’s 
medium, DMEM (Mediatech, Inc. Manassas, VA), supplemented with 10% heat-
inactivated fetal bovine serum (Gemini, Bio-Products, West Sacramento, CA) and 1X 
Penicillin/Streptomycin (Lonza, Walkersville, MD). Cells were grown at 37˚C in a water-
jacketed 5% CO2 humidified incubator (NuAire, Plymouth, MN). Cell line 658-D (kindly 
provided by Matthew Porteus, Standford University) is a HEK-293 derivative where 
plasmid pA658 was randomly integrated which contains a non-functional GFP gene 
under the CMV/CBA promoter(Porteus and Baltimore 2003). Plasmid pLDSL contains 




endonuclease preceded by 2 STOP codons. Plasmid p67 contains the I-SceI endonuclease 
gene expressed under the CMV/CBA promoter (Porteus and Baltimore 2003). Cells were 
transfected using polyethylenimine (PEI, Polysciences, Warrington, PA) transfection 
reagent in 24-well plates seeded at a density of ~150,000 cells per well (Grieger, Choi et 
al. 2006, Hirsch, Storici et al. 2009) 24 hours prior to transfection. In all transfection 
experiments in HEK-293 cells, the plasmid DNA was used in the amount of 0.5 µg for 
the expression vector as well as 0.5 µg for the targeted vector and the repairing DNA 
oligonucleotide used was 1 µg, unless otherwise indicated. For experiments in 658-D 
cells, 0.5 µg for the expression vector p67 and 1.5 µg of the repairing DNA 
oligonucleotide were used. In these experiments, the oligos and the plasmid were diluted 
in DMEM without supplements, vortexed in the presence of PEI, and then added to the 
wells 10-15 minutes later. Red fluorescent cells were visualized by fluorescent 
microscopy using a Zeiss Observer A1 microscope and an AxioCam MRm camera 
(Zeiss, Thornwood, NY). Frequencies of RFP and GFP positive cells were obtained by 
flow cytometric analysis using the BD FACS Aria II Cell Sorter (BD Biosciences, 
Sparks, MD) for RFP detection or the BD LSR II Flow Cytometer (BD BioSciences, 
Sparks, MD) for GFP detection only 5-8 days following transfection. Sequences of 







































Table 4.2 Oligonucleotides used for mammalian cells The table above shows the oligonucleotides used in HEK-293 and 658-D cell 




















 4.3.7 Yeast Strains 
Two different strain backgrounds were used for these studies, BY4742 (MATα  his3Δ1 
leu2Δ0 lys2Δ0 ura3Δ0) and 55R5-3C (MATa ura1). For the BY4742 background, TRP5, 
ADE2, and LEU2 loci were tested. For the 55R5-3C background, TRP1, ADE2, and 
LEU2 loci were tested.  
For the TRP5 locus (BY4742 background), yeast strains FRO-155 and FRO-526 were 
used. Yeast haploid strain FRO-155 (MATα his3Δ1 leu2Δ0 lys2Δ0 trp5::GSHU lys2::Alu 
IR) contains the GSHU CORE cassette (including the I-SceI gene under the 
inducible GAL1 promoter, the hygromycin resistance gene hyg, and the counterselectable 
URA3 gene from Kluyveromyces lactis (KlURA3) marker gene) and the I-SceI site (HOT 
site) in TRP5(Storici, Durham et al. 2003). FRO-526 is identical to FRO-155 except that 
instead of the CORE cassette GSHU, the TRP5 gene is disrupted with the CORE cassette 
UK (the counterselectable URA3 gene from Kluyveromyces lactis (KlURA3) marker 
gene along with the KanMX4 gene conferring G418 resistance). These strains, along with 
separate isolates FRO-156 (identical to FRO-155), and FRO-527 (identical to FRO-526) 
were used to characterize the TRP5 locus. 
All other strains were generated by integrating the CORE cassette GSH (including the I-
SceI gene under the inducible GAL1 promoter and the hygromycin resistance gene hyg) 
into each respective locus and strain background. For the strains to contain the I-SceI 




Durham et al. 2003) using primers with homology tails to the respective integration site 
along with the I-SceI site upstream of the GAL1 promoter. The strains lacking the I-SceI 
site were generated in the same way except with primers lacking the I-SceI site. 
 
4.3.8 Yeast Transformations 
Transformations were done as previously described with minor variations(Stuckey, 
Mukherjee et al. 2011). 50 ml of YPLac liquid culture was inoculated approximately 24 
hours prior to transformation and incubated with vigorous shaking at 30ºC. 
Transformations were done with 1 nmol of total oligo DNA. Sequences of 
oligonucleotides used for repair can be found in Table 4.3. Cells from each 
transformation were diluted appropriately and plated to synthetic complete medium 
lacking the respective amino acid and containing 2% galactose for I-SceI induction. 
Viability was assessed by diluting and plating control cells that did not contain 
oligonucleotides for repair on synthetic complete medium. 
4.3.9 Data presentation and statistics 
Graphs were made using GraphPad Prism 5 (Graphpad Software, Inc.). Data are plotted 
as mean values with 95% confidence intervals shown. Statistical significance was 








Sequence (aptamer in red) 
ISB7_TRP5_F54 90 5' GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG GGAAAAGGGTTTTGATGAAGCTGTCGCGGATCCCACATTCTG
GGAAGACTTCAA 3' 
ISB7_TRP5_F40 76 5' GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG GGTTTTGATGAAGCTGTCGCGGATCCCACATTCTGGGAAG 3' 
ISB7_TRP1_F54 90 5’ GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG GTGGCAAGAATACCAAGAGTTCCTCGGTTTGCCAGTTATTAA
AAGACTCGTATT 3’ 
ISB7_ADE2_F54 90 5’ GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG GGACATTATACCATTGATGCTTGCGTCACTTCTCAATTTGAAG
CTCATTTGAGA 3’ 
ISB7_ADE2_F40 76 5’ GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG ATACCATTGATGCTTGCGTCACTTCTCAATTTGAAGCTCA 3’ 
ISB7_LEU2_F54 90 5’ GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG CGCTTTCATGGCCCTACAACATGAGCCACCATTGCCTATTTGG
TCCTTGGATAA 3’ 
ISB7_LEU2_F40 76 5’ GCGGGCGCTGTTGACAGCGGTCAGGTGGATGGGATG ATGGCCCTACAACATGAGCCACCATTGCCTATTTGGTCCT 3’ 
P1P2_TRP5_F54 90 5' TTCTGCCCGCCTCCTTCCGACGAGATAGGCGGACAC GGAAAAGGGTTTTGATGAAGCTGTCGCGGATCCCACATTCTGG





Table 4.3 Oligonucleotides used for yeast The table above shows the oligonucleotides used in yeast. The aptamer sequence is shown 
in red.
P1P2_TRP5_F40 76 5' TTCTGCCCGCCTCCTTCCGACGAGATAGGCGGACAC GGTTTTGATGAAGCTGTCGCGGATCCCACATTCTGGGAAG 3'  
P1P2_TRP1_F54 90 5’ TTCTGCCCGCCTCCTTCCGACGAGATAGGCGGACAC 
GTGGCAAGAATACCAAGAGTTCCTCGGTTTGCCAGTTATTAAAAGACTCGTATT 3’ 
 
P1P2_ADE2_F54 90 5’ TTCTGCCCGCCTCCTTCCGACGAGATAGGCGGACAC 
CGCTTTCATGGCCCTACAACATGAGCCACCATTGCCTATTTGGTCCTTGGATAA 3’ 
 
P1P2_ADE2_F40 76 5’ TTCTGCCCGCCTCCTTCCGACGAGATAGGCGGACAC 
ATGGCCCTACAACATGAGCCACCATTGCCTATTTGGTCCT 3’ 
 
P1P2_LEU2_F54 90 5’ TTCTGCCCGCCTCCTTCCGACGAGATAGGCGGACAC 
CGCTTTCATGGCCCTACAACATGAGCCACCATTGCCTATTTGGTCCTTGGATAA 3’ 
 







4.4.1 Bulk affinity analysis and selection 
Serial dilutions of the aptamer library were made and the individual free DNA run time 
was determined (Figure 4.1). Next, we proceeded to combine I-SceI and DNA for a bulk 
affinity analysis (Figure 4.2). The bulk affinity analysis allowed us to visualize peaks 
corresponding to I-SceI DNA complexes. Knowing the migration times of these 
complexes along with the free DNA alone, a collection window could be determined 
stretching from the beginning of the first complex peak to the end of the last complex 
peak. In order to increase the stringency of the selection, the concentration of I-SceI was 
greatly reduced compared to the bulk affinity for the first round of selection. The amount 
of DNA used in the first round of selection was increased compared to the bulk affinity 
assay in order to increase the number of binding sequences. Despite the reduction in I-
SceI concentration, complexes were still observed for the first round of selection (Figure 
4.3). The fraction containing the aptamer-I-SceI complexes was collected and without 
amplification was used in a subsequent round of selection. In the second round of 
selection, the ratio of DNA forming a complex compared to free DNA was much higher 
than in the first round. Selection proceeded to a third round, but no complexes were 








Figure 4.2 DNA library run without protein. The random ssDNA library (1 µM) was 
run alone, in the absence of I-SceI. As can be seen the free DNA begins to appear at 






Figure 4.3 Bulk affinity assay for I-SceI aptamer selection. A bulk affinity assay was 
done with 1.5 µM I-SceI and 100 nM ssDNA aptamer library. The free DNA not bound 
to I-SceI has a run time of approximately 10 minutes. Prior to the free DNA peak there 










Figure 4.4 Non-SELEX Round 1, 2, and 3. The first round of Non-SELEX ran with a 
low concentration of I-SceI (100 nM) and a large concentration (50 µM) of ssDNA 
library. Even in the first round of selection, I-SceI DNA complex peaks could be detected 
prior to the free DNA. The second round of selection was done using the complexes 
collected in the first round. As can be seen for round 2, the amount of total DNA 
drastically decreased but there was still a complex peak that formed. In the third round of 






4.4.2 Post-selection processing of aptamers 
The collected DNA from the second round of selection containing the DNA I-SceI 
complexes underwent qRT-PCR amplification using primers flanking the internal random 
sequence. The forward primer, P1, amplified the aptamer-containing strand of interest, 
while the reverse primer, P2, amplified the non-aptamer complementary strand. In a 
previous protocol to select DNA aptamers, it was shown that over-amplification of the 
random library leads to formation of non-specific products [12], therefore the random 
library was only amplified to ~50% of the maximum yield as measured by qRT-PCR. 
After qRT-PCR analysis revealed the optimum number of cycles to amplify the collected 
DNA, a regular PCR using more of the collected DNA was performed with unlabeled P1 
and P2 primers. TOPO blunt-end cloning was performed with the aptamer pool and 
colonies were selected by growth on LB-kanamycin plates. Forty-eight colonies were 
chosen and plasmid DNA was crudely extracted. An asymmetric PCR was used on the 
extracted DNA to predominantly amplify the potential aptamer strand. The P1 primer that 
amplified the potential aptamer strand was FAM-labeled so the potential aptamer could 
be analyzed using CE with LIF. Potential aptamers were run with I-SceI and the strongest 
binding aptamers were selected for sequencing.  
 
After sequencing, several candidate aptamers to I-SceI, called “I-SceI strong binders” 
were ordered and P32-labeled for further characterization using electrophoretic mobility 




experiments. Of the candidate aptamers, three sequences were chosen for their ability to 
bind to I-SceI, namely I-SceI strong binder 4 (ISB4), I-SceI strong binder 7 (ISB7), I-SceI 
strong binder 10 (ISB10). Of these sequences, ISB7 showed the strongest binding 
through EMSA gels. These three sequences were then ordered as PAGE purified FAM-
labeled oligonucleotides and again underwent testing by CE with LIF. The binding 
affinities by CE were calculated to be ~3.16 µM for ISB7, ~52.49 µM for ISB4, and 
~5.83 µM for ISB10 by a method described previously(Berezovski and Krylov 2002). 
 
 
4.4.3 Characterization of I-SceI aptamers in yeast 
4.4.3.1TRP5 locus 
Oligonucleotides were ordered from Eurofins MWG Operon (Huntsville, AL) that 
contained the aptamer sequences from ISB4, ISB7, and ISB10 attached to the 5’ end of a 
DNA sequence containing 54 bases of homology to restore the disrupted TRP5 gene in 
yeast strains FRO-155 and FRO-526 described previously. The primer regions from the 
aptamer library were removed as they were not seen to influence binding (data not 
shown). In addition to the aptamer-containing oligonucleotides used to correct the TRP5 
gene a negative control not selected to bind to I-SceI was used. Due to the inability of the 
library primers P1 and P2 to bind I-SceI, these were used in place of the aptamer 





Using each of the different oligonucleotides to repair the TRP5 gene it was shown that 
the ISB7 aptamer-containing oligonucleotide significantly increased the level of gene 
correction compared to the negative control P1P2 and the other aptamer-containing 
oligonucleotides ISB4 and ISB10 in the FRO-155 strain where the I-SceI gene was 
expressed and the I-SceI site was present at the target site. FRO-526, the strain that did 
not have the I-SceI site and also did not express the I-SceI gene, showed no significant 
difference between the ISB7 aptamer-containing oligonucleotide and the negative control 
P1P2 or the other aptamer-containing oligonucleotides (ISB4 and ISB10). Also, because 
there was no DNA double-stranded break (DSB) in FRO-526 the level of gene correction 
was reduced several orders of magnitude. As an additional control, the strain containing 
the I-SceI gene and site was grown and plated to glucose media. Without galactose for the 
expression of I-SceI, there was no significant difference between the ISB7 aptamer-
containing oligonucleotide and the other oligonucleotides. 
4.4.3.2 Aptamer testing at various loci in yeast 
After the results from the TRP5 locus, testing was done at several other loci to verify this 
was not a locus specific event. In these new loci the ISB4 and ISB10 aptamers were not 
used since they did not show an increase in gene targeting at the TRP5 locus. At each of 
these loci the GSH cassette containing the I-SceI gene under the inducible GAL1-10 
promoter along with the hygromycin resistance gene hyg were integrated generating 
auxotrophs for the respective amino acid. For the BY4742 strain background, the ADE2 
and LEU2 loci were chosen, and for the 55R5-3C strain background, the TRP1, ADE2, 




integrated GSH cassette with the 18-bp I-SceI recognition site and one strain that had the 
cassette but did not have the I-SceI site. At every loci tested there was a significant 
increase in gene targeting with the ISB7 aptamer-containing oligonucleotide compared to 
the negative control P1P2 oligonucleotide when I-SceI was induced by galactose and the 
I-SceI site was present (Figure 4.4). There was an approximately 3-fold increase for the 
ADE2 locus, approximately 2-fold increase for the LEU2 locus, and approximately 2.5-
fold for the TRP1 locus. However, in the strains lacking the I-SceI site there was no 
significant difference between the oligonucleotides (Figure 4.5). Likewise, when the 
strains containing the I-SceI site were grown and plated to glucose-containing media 
there was no significant difference between the oligonucleotides (Figure 4.5).  
Seeing the increase in gene targeting using the ISB7 aptamer-containing oligonucleotide, 
it was postulated that by shortening the region of homology we might see an even greater 
effect from the aptamer. While shorter homology was expected to reduce the overall 
repair, it was expected that the fold-difference between the aptamer-containing 
oligonucleotide would increase relative to the non-binding oligonucleotide control. Due 
to the lower recombination level in the 55R5-3C strain background, the shorter 
oligonucleotides were only used in the BY4742 derived strains. By shortening the 
homology region of the oligonucleotide from fifty bases to forty bases, the level of repair 
decreased dramatically as expected (Figure 4.6). As we expected, the level of repair at 
the TRP5 locus using the shorter oligonucleotides showed a greater fold difference 
between the ISB7 aptamer-containing oligonucleotide and the P1P2 non-selected 
negative control (from six-fold to fifteen-fold). Unexpectedly, this was not the case for 





























Figure 4.5 Yeast transformation results. The strains containing the I-SceI break site as 
well as the I-SceI gene under the GAL1-10 promoter grown on galactose media. As can 
be seen, for every locus tested there was a significant increase in gene targeting using the 
aptamer-containing oligonucleotides compared to using the non-selected control. A) The 






























































































































































































































































Figure 4.6 Yeast transformation results. The strains with the I-SceI gene under the 
GAL1-10 promoter but lacking the I-SceI site (No Site). In addition, the strains with the I-
SceI break site were grown on glucose media, but since the I-SceI gene is under the 
galactose-inducible promoter it should not be expressed under this condition. As can be 
seen, for every locus tested there was no significant difference in gene targeting using the 
aptamer-containing oligonucleotides compared to using the non-selected control. A) The 
strains from the BY4742 background. B) The strains from the 55R5-3C background (no 










Figure 4.7 Yeast transformation with shorter oligonucleotides. The strains with the I-
SceI gene under the GAL1-10 promoter and the I-SceI site (all BY4742 strain 
background) were grown on galactose, inducing expression of I-SceI. In addition to using 
aptamer or non-selected control containing oligonucleotides with 54 bases of homology, 
shown before to stimulate gene targeting, shorter oligonucleotides with only 40 bases of 
homology were used. As expected, the level of overall repair decreased with the shorter 
oligonucleotides because they had less homology. The shorter TRP5 oligonucleotides 
showed a greater fold difference between the aptamer containing oligonucleotide and the 
non-selected control oligonucleotide. Unexpectedly, the shorter ADE2 and LEU2 
repairing oligonucleotides both showed no significant difference between the aptamer 







Figure 4.8 Yeast transformation with shorter oligonucleotides structural 
explanation. The shorter TRP5 oligonucleotides showed a greater fold difference 
between the aptamer containing oligonucleotide and the non-selected control 
oligonucleotide as expected. Unexpectedly, the shorter ADE2 and LEU2 repairing 
oligonucleotides both showed no significant difference between the aptamer and the non-
selected control containing oligonucleotides. Looking at the predicted secondary 
structures of the shorter aptamer containing oligonucleotides in the 5’ aptamer region the 




by several bases not predicted to form any secondary structure (similar to the longer 
ISB7_TRP_F54 oligonucleotide). However, for the shorter ADE2 oligonucleotide the 
proximity of the aptamer hairpin to a subsequent hairpin increases compared to the longer 
oligonucleotide which contained several single-stranded bases between the aptamer 
hairpin and the next hairpin. Lastly, while the LEU2 oligonucleotide overall structure 
does not seem to change much, the size of the internal loops of the hairpin following the 
aptamer hairpin decreases significantly compared to the longer oligonucleotide. The 
proximity of the subsequent hairpin following the aptamer hairpin for the LEU2 
oligonucleotide may explain why the aptamer at this locus, while significantly different 









A possible explanation for the unexpected results at the ADE2 and LEU2 loci with shorter 
oligonucleotides could be that by shortening the oligonucleotides the secondary structure 
of the oligonucleotide was changed and the formation of the aptamer was no longer 
energetically favorable. To investigate this possibility, secondary structure prediction 
software mFold was used on the oligonucleotides 
(http://mfold.rna.albany.edu/?q=mfold/dna-folding-form). The lowest free-energy (most 
stable) structures predicted for the ISB7 aptamer-containing oligonucleotides with 54-
base homology regions all formed the suspected aptamer hairpin near the 5’ end of the 
oligonucleotide (Figure 4.8). It was interesting to note, however, that while the TRP5 and 
ADE2 oligonucleotides had several bases without secondary structure following the 
aptamer hairpin the oligonucleotide to repair LEU2 contained only a single base between 
the aptamer hairpin and another stem-loop structure. This might explain why the LEU2 
oligonucleotide with the 54-base homology region, while still capable of increasing gene 
targeting, showed the least fold-difference in repair and was not as significantly different 
from the nonbinding control as either the ADE2 or TRP5 oligonucleotides. When 
analyzing the secondary structures of the ISB7 aptamer-containing oligonucleotides with 
40-base homology regions, there was a noticeable change in secondary structure for each 
of the oligonucleotides (Figure 4.8). However, for the shorter TRP5 oligonucleotide, the 
aptamer hairpin was still followed by several bases not predicted to form any secondary 
structure and hence not likely to interfere with the aptamer binding. This is consistent 
with the results seen in vivo. The ADE2 oligonucleotide with 54 bases of homology 
compared to the ADE2 oligonucleotide with 40 bases changed secondary structure such 




from six to one, bringing another stem-loop structure closer to the aptamer hairpin, 
possibly interfering with binding. The LEU2 oligonucleotide with 40 bases of homology 
had a similar structure to the LEU2 oligonucleotide with 54 bases of homology, except 
that the size of the internal loops for the stem-loop structure close to the aptamer hairpin 
were reduced. The reduction in the size of the loops may have altered the binding 
capabilities of the aptamer. The potentially altered binding of the LEU2 and ADE2 40-
base homology aptamer-containing oligonucleotides would explain the reduction in gene 
targeting with these oligonucleotides and highlight a disadvantage to our system. 
Although the aptamer stimulates gene targeting, the secondary structure of the aptamer 
must be taken into account when designing oligonucleotides for repair. 
 
4.4.4 Characterization of I-SceI aptamers in human cells 
After testing the ISB7 aptamer in yeast, we also tested the aptamer in human embryonic 
kidney (HEK-293) cells. We have a chromosomal assay for detecting repair of GFP in a 
monoclonal cell line derived from HEK-293 known as 658-D, described previously 
(Porteus and Baltimore 2003). The 54 bp of homology aptamer containing 
oligonucleotide generated to repair this locus was not predicted to have secondary 
structure in which the aptamer hairpin would form (Figure 4.9). Without the aptamer 
formation, it was not expected that there would be an increase in gene targeting. In the 
658-D cell line, as expected we did not see an increase in gene correction when 
transfecting an ISB7 aptamer-containing oligonucleotide and a plasmid for I-SceI 




containing the same disrupted GFP sequence used to generate the 658-D cell line in 
HEK-293 cells along with the expression vector and the ISB7 containing oligonucleotide 
or the non-binding control. Again, there was no increase in gene correction by the ISB7 
containing oligonucleotide over the non-binding control and again there was a significant 
decrease in repair.  Interestingly there was a significant increase in repair with the P1P2 
containing oligonucleotide over the ISB7 containing oligonucleotide.  An explanation for 
this increase could be that the secondary structure predicted for the ISB7 containing 
oligonucelotide is largely dsDNA (Figure 4.9), whereas the P1P2 containing 
oligonucleotide is mostly ssDNA, which was shown to be preferential for DSB repair in 










Figure 4.9 mFold structures for the GFP locus  In both the HEK-293 and the 658-D 
cell line there is a significant decrease in repair by the ISB7 containing oligonucleotide 
compared to the nonselected control P1P2 containing oligonucleotide.  Based upon the 
mFold predicted secondary structure it can be seen that the aptamer hairpin does not form 
for the ISB7 containing oligonucleotide.  Also, the P1P2 containing oligonucleotide is 
mostly single-stranded DNA, which was shown previously to be a better substrate for 








Figure 4.9 Testing of the ISB7 aptamer at the GFP locus in HEK-293 and 658-D 
cells. The GFP_F80 oligonucleotide does not contain the aptamer sequence or the non-
selected control but is used as a positive control because it has 80 bases of homology (40 
to either side of the DSB) to GFP. A) In the 658-D cell line there is a significant decrease 
in repair by the ISB7 containing oligonucleotide compared to the nonselected control 
P1P2 containing oligonucleotide which is also true for B) the plasmid based assay. C) 
Represents data from hand counting the number of GFP+ cells in each well and this data 
corroborates the flow cytometry data. The level of repair with the shorter 







In addition to testing at the GFP locus, the ISB7 aptamer was tested using a plasmid 
based assay to repair the red fluorescent protein, DsRed2. The assay consisted of 
transfecting a plasmid containing the DsRed2 gene disrupted with the I-SceI recognition 
site and two STOP codons along with the I-SceI expression vector and the 
oligonucleotides for repair of DsRed2. Unlike for the GFP locus, the secondary structure 
predicted for each of the ISB7 containing oligonucleotides used to repair DsRed2 
contained the aptamer hairpin. Using oligonucleotides containing the ISB7 aptamer and 
54 bases of homology to DsRed2, there was a significant increase in repair over the non-
binding control. As in yeast, oligonucleotides with shorter homology regions were 
designed and tested, this time using oligonucleotides with 40 bases of homology and 30 
bases of homology. Both the ISB7 aptamer containing oligonucleotides with 40 and 30 
bases of homology were predicted to form the aptamer hairpin. Similar to our results at 
the TRP5 locus in yeast, the shorter oligonucleotides increased repair relative to the 
corresponding shorter non-binding control sequence as measured by flow cytometry 
(Figure 4.10) beyond the difference seen with the longer oligonucleotide. In the case of 
the shortest oligonucleotides, those with only 30 bases of homology to DsRed2, the flow 
cytometer was unable to accurately detect the level of repair since it was too close to 
background levels. Hand counts of the RFP+ cells in each well were compared to the 
readings by flow cytometry. For the oligonucleotides with 54 and 40 bases of homology, 
the hand counts and the readings by flow cytometry were in agreement, but for the 
shorter oligonucleotides with only 30 bases of homology, the hand counts did not agree 




the hand counts for the ISB7 aptamer-containing oligonucleotide with 30 bases of 








Figure 4.11 Testing of the ISB7 aptamer at the DsRed2 locus in HEK-293 cells. A) 
Flow cytometry analysis reveals a significant difference between the ISB7 aptamer 
containing oligonucleotides and the non-selected P1P2 control oligonucleotides. When 
the homology length is shortened from 54 bases to 40 there is a greater fold difference 
between the ISB7 and P1P2 containing oligonucleotides. For the oligonucleotides with 30 
bases of homology, while the fold difference between the ISB7 aptamer containing 
oligonucleotide and the non-selected P1P2 control containing oligonucleotide is greater 
than the oligonucleotides with 54 bases of homology, it is less than the oligonucleotides 
with 40 bases of homology. The flow cytometer seems to have reached its lower 
detection limit and may be over reporting the number of RFP+ cells in the controls, the 
P1P2_DsRed2_F30 oligonucleotide, and the NT_DsRed2_F40 oligonucleotide; hence it 
is underreporting the fold difference. B) Represents data from hand counting the number 
of RFP+ cells in each well and this data corroborates the flow cytometry data except for 
those oligonucleotides previously mentioned as being over reported. Based upon the hand 










The system described here takes advantage of the fact that a single DNA molecule can 
have multiple functions. By constructing a single DNA molecule to contain both an 
aptamer region as well as a region to repair a genomic locus we were able to tether 
homologous DNA to the site-specific endonuclease I-SceI. In every genomic locus tested 
we stimulated gene targeting when the I-SceI site was present along with expression of 
the I-SceI endonuclease.  
Although I-SceI was chosen, protein-assisted targeting in principle could be applied to 
many other proteins. Other site-specific endonucleases, including modular endonucleases 
such as ZFNs, TALENs, or Cas proteins should theoretically also provide stimulation of 
gene targeting similarly to I-SceI. I-SceI generates a DSB in a site-specific manner, but 
alternatively to a site-specific protein, protein-assisted targeting could be used for other 
components of DSB repair that are not site-specific. For example, an aptamer to a general 
HR repair protein, such as Rad51, might provide an increase to gene targeting as well. 
Conversely, the mild but statistically significant stimulation of gene targeting even in the 
absence of Rad52 (data not shown) might mean that protein-assisted targeting could be 
used in an HR-independent fashion. The work described here represents a novel proof-of-












5.1 MAJOR FINDINGS 
 Selection of BSA aptamers using CE-SELEX without LIF 
 Selection of I-SceI aptamers using Non-SELEX with LIF 
 in vivo testing of I-SceI aptamer ISB7 reveals stimulation of gene targeting in 
both yeast and human cells 




Gene therapy has recently been gaining attention again after safety concerns in the early 
2000s slowed, and in some cases halted, its progress due to the death of a clinical trial 
subject and the development of a leukemia-like disorder in several patients (Thomas, 
Ehrhardt et al. 2003). One of the major problems of gene augmentation therapy, the most 
commonly taken approach to gene therapy, is the possibility of insertional mutagenesis of 
the transgene. Random integration of foreign genetic material is the normal outcome for 
exogenously introduced DNA, but it presents a risk for any gene therapy patient. 




In addition to the safety problem random integration poses, gene augmentation is also 
limited from a researcher’s perspective. In order to study the function of a gene, addition 
of another copy of that gene will provide little or no information. Gene targeting is 
essential for research because it allows for the deletion and/or modification of 
endogenous genes, which cannot be achieved with random integration. 
 
As described in the introduction, there are currently many different strategies for 
increasing gene targeting, but all of these strategies are harmful in some way. Increase of 
gene targeting by a DSB can introduce mutations in cells that do not undergo 
homologous recombination. Additionally, DSBs, generated by homing endonucleases 
(Petek, Russell et al. 2010), ZFNs(Pattanayak, Ramirez et al. 2011) (Gabriel, Lombardo 
et al. 2011), or TALENs (Hockemeyer, Wang et al. 2011) all have off-target cleavage 
which presents a safety concern for mutagenesis beyond the targeted site. Increase of 
gene targeting by over-expression of recombination proteins from HR proficient 
organisms could also lead to unwanted recombination elsewhere in the genome (Di 
Primio, Galli et al. 2005). In the same way, the increase of gene targeting by knocking 
down or knocking out expression of key NHEJ proteins could lead to increased 
recombination at unwanted sequences. Also, knocking down or knocking out key NHEJ 
proteins, while increasing gene targeting, limits the cell’s ability to repair DSBs which in 
most cases leads to a hypersensitivity to DNA damage (Adachi, Suzuki et al. 2003). A 
third reason that knocking down or knocking out classical NHEJ proteins could be 




mutagenic end-joining or micro-homology mediated end-joining (MMEJ), which would 
increase mutations on a genome-wide scale (Bindra, Goglia et al. 2013). 
 
In order to address the need for a safer, more effective means to increase gene targeting 
we began this project of protein-assisted targeting. There were two parallel strategies 
employed, the use of two proteins capable of binding to DNA, specifically the GAL4-
DBD and the I-SceI endonuclease, as well as the strategy using a DNA aptamer to I-SceI. 
The GAL4-DBD I-SceI fusion protein was unable to be expressed which limits our 
understanding of the efficacy of protein-assisted targeting using this strategy. The DNA 
aptamer to I-SceI strategy relied on the successful selection of a DNA sequence capable 
of binding to I-SceI. After several attempts with traditional SELEX (see APPENDIX A) 
we were successful in generating a high affinity aptamer to I-SceI using a modification of 
capillary electrophoresis (CE)-SELEX. Use of this aptamer as part of a longer DNA 
molecule that contained homology to a target sequence stimulated gene targeting in every 
locus tested when the aptamer secondary structure was able to form. In yeast cells, the 
aptamer stimulated repair up to 15-fold over the non-binding control and in mammalian 
cells, the aptamer stimulated gene targeting up to 16-fold over the control. The system we 
have developed represents an effective way to increase gene targeting. 
 
Protein-assisted targeting provides a strategy that increases gene targeting, in a way that 




targeting DNA to a protein does not cause any damage to the endogenous DNA targeted 
and should not increase recombination outside of the targeted area. For the purposes of 
gene targeting, it benefits us to reduce NHEJ (Iiizumi, Kurosawa et al. 2008) (Bertolini, 
Bertolini et al. 2009), but it is clear that doing so on a genome-wide scale is harmful to 
the cell. Our strategy deals with the problems associated with NHEJ while at the same 
time not affecting NHEJ outside of the targeted gene. Using our system random 
integration should decrease because the exogenously introduced DNA, when bound to I-
SceI, is now specifically targeted to the I-SceI site while at the same time the DNA 
attached to the protein may be sterically hindered to randomly integrate. Also, by 
bringing the targeting DNA into close proximity of the DSB, NHEJ relative to HR may 
decrease. 
 
In addition to the efficacy of our system at increasing gene targeting while 
simultaneously decreasing random integration, the uniqueness of the concept provides 
benefits of its own. Protein-assisted targeting uses DNA aptamers, which themselves are 
a relatively new discovery with aptamer selection only being done since the early 1990s 
(Tuerk and Gold 1990) (Ellington and Szostak 1990). Aptamers have been used as 
biosensors (Cheng, Ge et al. 2007) (Stojanovic and Kolpashchikov 2004) and as 
therapeutics (Barbas, Mi et al. 2010) but their use can be simplified to binding and 
fluorescing (sensor) or binding and inhibiting (therapy) or binding and being endocytosed 
(therapy). Our aptamer for I-SceI binds and is targeted to a specific DNA site. This 




The novelty and uniqueness of our system lays the foundation for other systems to come. 
By showing increased gene targeting with our I-SceI aptamer, others could select 
aptamers for other site-specific endonucleases including recently popular modular 
endonucleases such as ZFNs, TALENs, and CRSPR systems. The potential aptamer 
targets are not limited to endonucleases but theoretically any protein involved in 
recombination. Finally, perhaps the most exciting aspect of the novelty of our system is 
that because it is stimulating gene targeting by a different means than the other systems 
described, our protein-assisted targeting strategy can be used in conjunction with these 
systems. We have shown that our system increases gene targeting in human cells with a 
DSB, but it is possible that gene targeting can be stimulated even further with a DSB and 
transient knock-down of NHEJ or overexpression of HR proteins from HR proficient 
organisms.  
 
A PubMed search of “DNA aptamer” or “RNA aptamer” in the title reveals only 374 
papers. Assuming that not all of these aptamers are for unique targets, the number of 
aptamers is very low. There could be several reasons for the lack of aptamers discovered, 
but probably the largest hurdle would be the selection process. The difficulty of selection 
poses a deterrent to many researchers attempting to select for an aptamer. Another likely 
reason why the number of aptamers is low is because there are several well-characterized 
aptamers (to thrombin, PMSA, theophylline, etc.) that are used in a variety of 
applications and it is “safer” to study something well-characterized and use it instead of 
investing much time and energy to risk not even selecting strong-binding aptamers. Our 




of aptamer targets, namely DNA binding proteins. Not only did we select a new kind of 
aptamer, we also used this aptamer to affect a functional change in vivo using our protein-
assisted targeting system. The protein-assisted targeting system we have developed has 
introduced a new area of aptamer-based research. Our system can be used as a model to 
other researchers interested in using aptamers to stimulate gene targeting. 
 
5.3 FUTURE DIRECTIONS 
 
The system developed here demonstrates a proof-of-principle for the concept of protein-
assisted targeting, and based upon this initial work further studies to elucidate, validate, 
and improve the system will logically follow. For example, there is the limitation we 
found with the aptamer system whereby different single-stranded homology regions may 
disrupt the aptamer region’s secondary structure to inhibit binding. To address the 
question of aptamer modularity in terms of different homology regions, there are several 
potential directions. Perhaps the most straightforward solution would be to anneal the 
homology region to its complementary sequence, such that the aptamer region would 
exist as a 5’ single-stranded tail to a mostly double-stranded oligonucleotide. This would 
eliminate annealing between the aptamer region and the homology region to form a non-
aptameric secondary structure. This strategy would be effective in systems where dsDNA 
is favorable to ssDNA, but unfavorable for systems where ssDNA is favored as a repair 
substrate. A second possibility is that a linker region could be designed between the 
aptamer and the homology regions. Several linker regions could be envisioned, the 




the homology region, or other linkers such as a sulfide linker (Chu, Twu et al. 2006) or a 
carbon linker (Zhou, Neff et al. 2013)between the two nucleic acids. 
   
There are several potential ways to increase the efficiency of our system from the 
standpoint of the DNA targeting molecule. Oligonucleotide stability, which could be a 
limitation to gene correction, could be enhanced by changing the chemistry of the 
oligonucleotides. Oligonucleotide modification (such as the use of phosphothioate 
linkages, addition of a 5’ cap, 3’ thiophosphate, etc.) could improve the stability of the 
oligonucleotides which could improve gene targeting frequencies. Another way to bolster 
the gene targeting efficiency of the system would be to use purified oligonucleotides 
instead of the non-purified oligonucleotides used in our studies. Non-purified 100-mer 
oligonucleotides synthesized at a coupling efficiency of 99.5% will contain only 60% 
full-length product, with the other 40% being truncated oligonucleotides (Stafford and 
Brun 2007) (truncated at the 5’ end of the oligonucleotide, which in our system would be 
the aptamer region). Preliminary data suggests that use of PAGE purified 
oligonucelotides does increase the level of repair of the aptamer oligonucleotide as 
compared to the control (data not shown). Additionally, the aptamer itself could be 
improved for enhanced binding to I-SceI. Although the aptamer was selected from a large 
pool of oligonucleotides, only ~10
14





 potential sequences, meaning that less than 1 sequence for every 5 million 
possible sequences was tested. This raises the possibility that the strongest binder to I-




modifications to the ISB7 aptamer sequence might lead to a further increase in gene 
targeting. 
 
In addition to improvements that could be made to the oligonucleotide sequence of the 
aptamer, verification of the binding could be done by altering the protein at the site of 
aptamer binding. Electrostatic mapping of the I-SceI protein, along with analysis of the I-
SceI structure, could potentially reveal epitopes of the DNA aptamer ISB7. Mutagenesis 
of these epitopes would lead to a change in the binding affinity of the aptamer and thus 
confirm the binding site of our ISB7 aptamer. Although there are several different 
improvements that could be made to the current aptamer for I-SceI, as stated previously a 
more modular system could be achieved using a different aptamer, to a designer 
endonuclease such as a ZFN or TALEN. Aptamer technology is constantly evolving and 
hopefully will continue to be a factor in not only biochemistry but also in the field of 
molecular biology. The system we developed here will act as the foundation for future 









SUPPLEMENTARY MATERIALS FOR CHAPTER 5 
A.1 SELEX procedure using magnetic beads  
 
Preliminary Work 
1. Design the oligo (our oligo has 20 bp primers on either end and a 50 bp variable 
NNNNNN region) and order it PAGE purified 
2. Order the magnetic beads that will bind to the protein (for our purpose we are 
using carboxyl terminated magnetic beads from Bangs Laboratory BM570 that come in a 
kit BP611) 
3. Follow the procedure for protein coupling from Bangs Laboratory 
4. Make the binding buffer by adding NaPO4 0.1M, MgCl2 0.01M, and NaCl 0.01M 




5. Starting with 10nmol of purified oligo, place in PCR machine and denature DNA 
at 95C for 5 minutes to eliminate any double stranded DNA 
6. Put the DNA on ice for 10 minutes 
7. Wash the protein and beads (which should have coupled) 3 or more times with the 
tris binding buffer to eliminate any leftover storage buffer. Aspirate (remove with pipette) 
the supernatant (liquid) each time after washing and vortexing. 
8. Continue until there is no suspension after vortexing (clear buffer only) 




10. Aspirate unbound DNA into a labeled Eppendorf tube after using the magnet to 
hold the beads in place 
11. Wash the bound oligo and beads (coupled with the protein) with 100 microliters 
of binding buffer 
12. Remove unbound oligo and repeat 11 two more times 
13. Add 100 microliters of binding buffer and then heat inside the PCR machine at 
95C for 10 minutes 
14. Transfer this supernatant into a tube labeled “bound oligo” 
15. Precipitate DNA with ethanol (100%) at -80C 
16. Leave at -80C for 30 minutes 
17. Centrifuge at MAX for 10 minutes 
18. Aspirate the ethanol, leaving the pellet 
19. Use 95% ethanol to wash (use pipette to wash) 
20. Vortex the pellet with the 95% ethanol 
21. Mash the pellet 
22. Vortex again 
23. Centrifuge at MAX for 5 minutes 
24. Vortex and mash until you have a good pellet 
25. Aspirate the ethanol 
26. Dry in SpeedVac for 30 minutes 
27. Resuspend the pellet in 50 microliters of sterile water 
28. Vortex H20 and the pellet 
29. Mash the pellet 
30. Vortex 








32. Add 1 microliter of Roche Taq polymerase 
5 microliters of Mg+2 buffer (10X concentrated) 
0.5 microliters of 50 mM DNTPs 
0.5 microliters of 100 mM P1 (the primer starting at the 5’ end of the oligo) 
0.5 microliters of 100 mM P2 
10 microliters of the pellet/H2O 
32.5 microliters of sterile H2O 
 
Total = 50 microliters 
 
Cycle = 1. 94C for 2 minutes 
2. 94C for 15 minutes 
3. 44C for 15 minutes 
4. 72C for 30 minutes 






33. After the 1
st
 PCR, then perform an asymmetric PCR. Instead of using equal 
amounts of each primer, we use 100 times more of the forward primer so that we end up 
with only the sequences we want and not their reverse complement. 
 
 
 Add 1 microliter of Roche Taq polymerase 
5 microliters of Mg+2 buffer (10X concentrated) 




0.5 microliters of 100 mM P1 (1 uM final) 
X microliters of 100 mM P2 (want 0.01 uM final) 
25 microliters of oligos from PCR1 
X microliters of sterile H2O (can’t know till P2 is calculated) 
Total = 50 microliters 
 
Cycle = 1. 94C for 2 minutes 
5. 94C for 15 minutes 
6. 44C for 15 minutes 
7. 72C for 30 minutes 
 




34. PCR product 2 is used (10 nmol) in the next round of SELEX 
35. Every five rounds of SELEX (starting with the first), use 250 uCi P32 labeled 
dATPs (1 uL) and then measure 
 
% = oligo bound /  unbound + bound + beads 
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